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Abstract 
 
EFFECTS OF CANNABINOID RECEPTOR INTERACTING PROTEIN (CRIP1a) ON 
CANNABINOID (CB1) RECEPTOR FUNCTION. 
 
By Tricia Hardt Smith, B.S., M.S. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2009. 
 
Major Director:  Dana E. Selley, Ph.D., Department of Pharmacology and Toxicology 
 
 This dissertation examines modulation of cannabinoid CB1 receptor function by 
Cannabinoid Receptor Interacting Protein (CRIP1a), a novel protein that binds the C-
terminus of CB1 receptors.  In Human embryonic kidney cells expressing human CB1 
receptors (hCB1-HEK) and hCB1-HEK cells stably co-expressing CRIP1a (hCB1-HEK-
CRIP1a), quantitative immunoblotting revealed a CRIP1a/CB1 molar ratio of 5.4 and 0.37, 
respectively, with no difference in CB1 receptor expression.  To test the hypothesis that 
CRIP1a modulates CB1 receptor signaling, G-protein and effector activity were examined 
with and without full, partial and inverse agonists.  [
35
S]GTPS binding, which measures 
G-protein-coupled receptor (GPCR)-mediated G-protein activation, showed that CRIP1a 
inhibited constitutive CB1 receptor activity, as indicated by the decreased effect of the 
inverse agonist SR141716A.  CRIP1a also decreased CB1 receptor-mediated G-protein 
activation by high efficacy agonists, whereas moderate and low efficacy agonists were 
unaffected.  In experiments varying Na
+
 concentration, CRIP1a decreased spontaneous G-
protein activation at low Na
+ 
concentrations, where spontaneous GPCR activity is 
highest.  This effect was eliminated by pertussis toxin pre-treatment, indicating that 
CRIP1a only inhibits GPCR-mediated activity.  To determine whether CRIP1a modulates 
xv 
 
receptor adaptation, hCB1-HEK (±CRIP1a) cells were pretreated with WIN or THC.  Both 
ligands desensitized CB1 receptor-mediated G-protein activation, but desensitization was 
unaffected by CRIP1a.  In contrast, CRIP1a attenuated downregulation of CB1 receptor 
binding sites by WIN, but not THC.  Downstream, CRIP1a attenuated constitutive CB1 
receptor-mediated inhibition of cAMP, as indicated by elimination of SR141716A-
stimulated cAMP, without affecting agonist-induced cAMP inhibition.  Constitutive 
inhibition was not due to endocannabinoids because LC-ESI-MS-MS did not detect 
endocannabinoids in hCB1-HEK (±CRIP1a) cells.  To determine whether effects of 
CRIP1a were conserved among cell types, Chinese Hamster Ovary cells expressing CB1 
receptors were stably co-transfected with CRIP1a, and had a CRIP1a/CB1 receptor molar 
ratio of 15 and 1900 with and without CRIP1a over-expression, respectively.  In this 
model, CRIP1a inhibited constitutive CB1 receptor-mediated G-protein activity, but 
activation by agonists was enhanced, suggesting CRIP1a effects were dependent on 
stoichiometry of CRIP1a/CB1 receptor or cell type.  Overall, these results indicate that 
CRIP1a decreases constitutive CB1 receptor activity, modulates agonist efficacy, and 
inhibits CB1 receptor downregulation, in a ligand- and cellular environment-dependent 
manner. 
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Chapter 1.  Introduction 
 
1.1 Introduction to Cannabinoids and the Cannabinoid Receptors 
 Cannabis, or marijuana, use has been documented in human history as early as 
2600 B.C. when in ancient Chinese texts, such as the Nei Ching, its use was 
recommended in cramping, pain, and to stop hemorrhage during childbirth.  Cannabis 
was also used in ancient Egypt for a variety of medical reasons, including childbirth, 
enemas, eye medications and ointments in bandages.  Ancient Indian texts, as early as 
1200 B.C., describe cannabis as a sacred grass, from which bhang, the drink prepared 
from cannabis, is used for its anxiolytic properties, „antiphlegmatic‟ properties and in 
religious rites.  In the 19
th
 century its use spread to Europe and the Americas as a 
psychoactive substance.  The medical utilization of cannabis also flourished during these 
times, until cannabis was banned in 1937 due to concerns over its abuse potential 
(Mechoulam 1986).  Recently, an 11 g sample of ancient cannabis was found in a 2700-
year-old tomb excavated in China.  High performance liquid chromatography confirmed 
the presence of psychoactive constituents, verifying cannabis use for medicinal or 
divinatory purposes early in human history (Russo et al. 2008).   
 In 1988, the main psychoactive component of marijuana, 9-tetrahydrocannabinol 
(THC) was found to exert its affects by binding to cannabinoid (CB) receptors in the 
brain (Devane et al. 1988).  Currently, the potential medical benefits of cannabinoids and 
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the endocannabinoid system are on the forefront of drug discovery (Mackie 2006). 
Dronabinol, a synthetic form of THC, has been proven affective in cancer patients for 
chemotherapy-induced nausea and vomiting.  Dronabinol is also used to treat AIDS-
related anorexia.  Other therapeutic effects of the drug include analgesia, antitumor 
effects, mood elevation, muscle relaxation, and relief of insomnia (Walsh et al. 2003).  
Human placebo-controlled trials of the drug Sativex, a buccal spray containing THC and 
another cannabinoid cannabidiol, have proven effective for the spasticity and neuropathic 
pain associated with multiple sclerosis (Barnes 2006).  The upregulation of the 
endocannabinoid pathway in response to neuronal injury has sparked interest in the use of 
cannabinoids in neurodegenerative disorders (Bahr et al. 2006).  CB1 receptor antagonists 
have shown promising results in anti-obesity studies (Palamara et al. 2006).  Overall, the 
CB1 receptor is an important therapeutic target that warrants further study.  
Understanding how the CB1 receptor is regulated may allow the selective targeting of 
beneficial effects while decreasing unwanted side effects, such as anxiety, short-term 
memory impairment and decreased motor coordination.   
Cannabinoid receptors are of particular importance in the arena of drug abuse.  
Cannabis is the most commonly used illicit drug in the United States, with more than 
40% of Americans age 12 and older having tried cannabis at least once (Administration 
2003).  In addition to mediating the effects of THC, cannabinoid receptors are also 
involved in mediating the rewarding properties of other drugs.  The cannabinoid and 
opioid system modulate each other‟s ability to activate dopamine (DA) release in the 
ascending mesocorticolimbic projections of the ventral tegmental area (VTA), which is 
activated by most drugs of abuse (Maldonado and Rodriguez de Fonseca 2002; 
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Maldonado et al. 2006).  In mice with a genetic knockout of CB1, the major cannabinoid 
receptor in the CNS, the reinforcing effects of morphine were reduced in intravenous 
self-administration tests (Ledent et al. 1999).  The CB1 receptor is also of importance in 
nicotine addiction, as CB1 knockout in mice blocked the rewarding properties of nicotine 
in conditioned place preference studies (Castane et al. 2002).  In addition, cannabinoid 
agonists stimulate voluntary alcohol consumption in alcohol-preferring Sardinian and 
Wistar rats (Gallate et al. 1999; Colombo et al. 2002).  Although CB1 knockout mice did 
not exhibit decreased self-administration of cocaine and amphetamine acutely (Cossu et 
al. 2001), they did show evidence of lower cocaine reinforcing efficacy on a progressive 
ratio schedule of self-administration (Soria et al. 2005).  This type of schedule evaluates 
the reinforcing strength of a drug, and lower break points indicate a decreased motivation 
for maintaining cocaine-seeking behavior.   
Rimonabant, a CB1 antagonist also known as SR141716A, has shown 
considerable promise as a drug addiction treatment.  Rimonabant decreased opioid self-
administration (Navarro et al. 2001) and conditioned place preference in rodents (De 
Vries et al. 2003). In human studies, rimonabant was significantly effective in tobacco 
cessation studies in North America [Studies with Rimonabant and Tobacco use in North 
America (STRATUS-North America)] and Europe (Fernandez and Allison 2004).  
Rimonabant reduced conditioned reinstatement of ethanol-seeking behavior in rats 
(Cippitelli et al. 2005), and decreased cocaine relapse after cocaine re-exposure (De Vries 
and Schoffelmeer 2005). 
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1.2 Cannabinoid Receptor Location, Function and Ligands 
 Two cannabinoid receptors have been cloned to date; CB1 (Matsuda et al. 1990) 
and CB2  (Munro et al. 1993).  CB1 is one of the most abundant receptors in the brain 
(Ester Fride 2003), and  it is also found in the periphery (Devane et al. 1988).  CB2 is 
found mainly within the immune system (Munro et al. 1993) and has limited expression 
in the central nervous system (CNS) (Van Sickle et al. 2005).   
 CB1 receptors are found throughout the central nervous system, with particularly 
high expression densities in the hippocampus, cortex, caudate-putamen, globus pallidus, 
substantia nigra and cerebellum, and with moderate expression in periaquidctal grey, 
spinal cord and hypothalamus (Herkenham et al. 1991; Sim et al. 1996; Tsou et al. 1998).  
The immediate effects of marijuana intoxication reflect the functions of these brain 
regions, including impairment of short term memory, emotional disruption, hypomotility, 
reward, catalepsy, decreased motor coordination, antinociception and hypothermia 
(Dewey 1986; Hollister 1986).   
The various cannabinoid ligands show a strong correlation between their affinity 
for CB1 receptor binding and their potency for in vivo effects (Compton et al. 1993).  CB1 
receptors have also been linked to a myriad of processes including brain development 
(Rueda et al. 2002), short-term synaptic plasticity (depolarized-induced suppression of 
inhibition (DSI) (Wilson and Nicoll 2001) and depolarized-induced suppression of 
excitation (DSE) (Kreitzer and Regehr 2001), and facilitation of long term potentiation 
(Carlson et al. 2002).  
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Figure 1.  The chemical structures of cannabinoid ligands.  Phytocannabinoids include 
9-tetrahydrocannabinol (THC), cannabidiol (CBD), and 9-tetrahydrocannabivarin 
(THCV).  Classic synthetic cannabinoids include HU210 and nabilone.  A non-classical 
synthetic cannabinoid is CP 55,940. An aminoalkykindol is WIN 55,212-2.  A nantradol 
is levonantradol.  Endogenous cannabinoids (eicosanoids) include anandamide (AEA) 
and 2-arachidonoyl glycerol (2-AG).  The diarylpyrazoles, which are inverse agonists, 
include SR141716A (SR1) and SR144528 (SR2). 
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 The first ligands discovered for the CB1 receptor were isolated from the Cannabis 
plant, and are termed phytocannabinoids; the main psychoactive component isolated from 
Cannabis being 9-tetrahydrocannabinol (THC) (Gaoni and Mechoulam 1971) (Figure 1).  
The discovery that the l-stereoisomer of THC, and not the d-stereoisomer, was 
responsible for the biological activity of THC suggested the involvement of a receptor, as 
drug-receptor interactions are stereoselective (Hollister 1974).  The involvement of a 
receptor was later confirmed by saturable, high affinity, stereospecific binding sites for 
the cannabinoid radioligand [
3
H]CP 55,940 in mouse brain membranes (Devane et al. 
1988).  Cannabidiol (CBD), a phytocannabinoid found in high abundance in Cannabis, 
has a very low affinity for cannabinoid receptors but does act as an antagonist of 
cannabinoid receptor agonists (Thomas et al. 2007).   Therapeutically, cannabidiol is not 
psychoactive, but is effective in the treatment of convulsions, inflammation, nausea and 
anxiety (Mechoulam et al. 2007).  9-Tetrahydrocannabivarin (THCV), also highly 
abundant in Cannabis, is a behaviorally active phytocannabinoid that acts as an weak 
partial agonist at CB1 receptors, and is able to antagonize the effects of THC (Pertwee et 
al. 2007). 
A myriad of synthetic cannabinoids have been synthesized (Figure 1), including 
synthetic classical cannabinoids that are structurally similar to THC, including HU210, 
which is greater than 100 times more potent than THC and has a longer duration of action 
(Felder et al. 1995).  Another synthetic cannabinoid similar to THC, nabilone, marketed 
as Cesmet, is approved for use nausea and vomiting associated with cancer chemotherapy 
(Slatkin 2007).  Non-classical synthetic cannabinoids that are somewhat structurally 
dissimilar to classical cannabinoids have also been synthesized, including the bicyclic CP 
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55,940 (CP) which is greater than 100 times more potent than THC in behavioral tests 
(Wiley et al. 1995) and CB1 receptor binding (Gatley et al. 1997).  Another non-classical, 
synthetic class of cannabinoids is the aminoalkylindoles, such as WIN 55,212,2 (WIN), 
which are structurally dissimilar to classical or bicyclic cannabinoids, yet bind potently to 
CB receptors and elicit strong behavioral effects (Kuster et al. 1993; Pacher et al. 2006).  
In the 1980s, Pfizer Pharmaceuticals introduced another structural class somewhat similar 
to the THC class termed the nantradols, which includes levonantradol and 
dextronantradol.  Levonantradol (Levo) is equipotent to 30 times more potent than THC 
in behavioral tests, while dextronantradol is weak to inactive (Little et al. 1988). 
In 1992, the first endogenous ligand for the CB1 receptor was discovered, N-
arachidonoyl ethanolamine.  This compound was also named anandamide, after the 
Sanskrit word ananda, meaning “bliss, delight”. (Devane et al. 1992).  Three years later 
another endogenous cannabinoid, 2-arachidonoylglycerol (2-AG) was independently co-
discovered (Mechoulam et al. 1995; Sugiura et al. 1995).  Anandamide is modestly 
selective for the CB1 receptor.  Anandamide may be partially synthesized in vivo via N-
acyl phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) in response to 
elevations of intracellular Ca
+2
.  However, NAPE-PLD knock-out mice were still able to 
produce reduced levels of N-acyl ethanolamines, suggesting that alternative pathways for 
the synthesis of anandamide exist (Leung et al. 2006).  Anandamide is broken down by 
fatty acid amide hyrdrolase (Cravatt et al. 2001).  2-AG binds to CB1 and CB2 with 
similar affinities, and is synthesized from diacylglycerol by diacyglycerol lipase (DAGL) 
(Bisogno et al. 2003), and is broken down primarily by monoacylcyclyceride lipase 
(MGL) (Dinh et al. 2002).  Many other endogenous lipids with endocannabinoid activity 
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have also been reported (Bisogno et al. 2005; Pacher et al. 2006).  One example is 2-
arachidonyl glyceryl ether, commonly known as noladin ether (Nol Eth), which was 
isolated from porcine brain in 2001.  It is psychoactive and binds strongly to the CB1 
receptor and weakly to the CB2 receptor (Hanus et al. 2001).  
The first CB1 receptor antagonist, discovered by Sanofi Aventis, was the 
diarylpyrazole SR141716A (SR1) (Rinaldi-Carmona et al. 1994).  This development was 
followed by the discovery of another diarylpyrazole selective for the CB2 receptor, 
SR144528 (SR2) (Rinaldi-Carmona et al. 1998).  Both antagonists were later shown to 
have inverse agonist properties, meaning that they inhibit the basal, agonist independent 
activity of the receptor to which they bind (Bouaboula et al. 1997; Bouaboula et al. 
1999). 
1.3 Cannabinoid Receptor Signaling 
 Cannabinoid receptors are members of the G-protein coupled receptor (GPCR) 
superfamily, which are proteins with seven transmembrane alpha-helical domains, as well 
as an extracellular N terminus and an intracellular C-terminus (Matsuda et al. 1990). 
These membrane bound receptors are activated by extracellular ligands, transducing the 
signal to the cell interior by activation of heterotrimeric guanine nucleotide bindin G-
proteins (G-proteins) (Gilman 1987).   The cannabinoid receptors specifically activate the 
pertussis (PTX) toxin sensitive Gi/Go subfamily of proteins, (Howlett et al. 1986), of 
which there are four types: Gi1, Gi2, Gi3, and Go (Albert and Robillard 2002). 
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Figure 2.  G-protein coupled receptor signaling.  Prior to ligand binding, the receptor is 
inactive and G-proteins exist in the form of an  heterotrimer.  The inactive G 
subunit is bound to GDP.  Upon ligand activation, the receptor changes to an active 
conformation (green), thereby activating G-proteins.  GDP is exchanged for GTP and the 
G and G dissociate from one another and the receptor and are free to activate 
downstream signaling events.  The cycle concludes when the GTPase activity of the G 
subunit dephosphorylates GTP to GDP, allowing the G subunit to return to its resting 
confirmation and reassociate with G. 
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A basic introduction to GPCR signaling is as follows (Figure 2).  Prior to 
activation, G-proteins exist in the form of an  heterotrimer, and are associated with 
the membrane via post-translational lipid moieties (Chen and Manning 2001).  The G 
subunit is bound to GDP.  Upon ligand binding, the receptor changes conformation, and 
becomes activated, thereby activating the G-protein.  GDP is exchanged for GTP, and the 
G and the G subunits dissociate from one another and the receptor and are free to 
activate downstream signaling events. The G and G remain bound to each other as a 
dimer.  The cycle concludes when the GTPase activity of the G subunit 
dephosphorylates GTP to GDP, allowing the G subunit to return to its resting 
conformation.  G and G reassociate, returning the G-protein to its original inactivated 
state (Rockhold 2002).  GPCRs act catalytically; each GPCR can activate multiple G-
proteins over time.  For instance the catalytic amplification factor of the cannabinoid CB1 
receptor has been calculated as 3 in striatum, as determined by comparing the Bmax value 
of agonist binding to the Bmax value of agonist-simulated [
35
S]GTPS binding.  It is 
important to note that although this calculated amplification factor might not be true 
under all conditions, it is useful to compare among different receptors in the same tissue 
when assayed under identical conditions.  For example, cannabinoid receptors exhibited 
low catalytic amplification factors compared to the µ-opioid and -opioid receptors in the 
striatum, which exhibited an amplification factor of 17 and 22, respectively (Sim et al. 
1996).  Moreover, the amplification factor of CB1 receptors, calculated by this same 
approach, varied among different brain regions (Breivogel et al. 1997). 
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Figure 3.  Equilibrium ternary complex model of ligand-receptor-G-protein interaction.  
GPCRs exist in equilibrium between an inactive (R) and active (R*) state.  The 
isomerization from R to R* enables GPCRs to dissociate from GDP from G-proteins (G), 
which is the rate limiting step in GPCR signaling.  The conversion from R to R* may 
happen in the presence of an agonist (A) or spontaneously, in the case of constitutively 
active receptors.  After GDP dissociation, GTP binds to the G subunit of the G-protein 
heterotrimer, causing its dissociation into the active components of GGTP, G, and its 
dissociation from the receptor. 
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Despite the seeming simplicity of the G-protein activation cycle, the nuances 
generated by the multitude of binding equilibria for all the possible protein-protein and 
ligand-protein interactions are more accurately represented in the equilibrium ternary 
complex model of ligand-receptor-G-protein interaction (Figure 3) (Leff 1995; Leff et al. 
1997; Howlett 2004; Mukhopadhyay and Howlett 2005).  GPCRs exist in equilibrium 
between an inactivate (R) and active state (R*) (Leff 1995).  The isomerization from R to 
R* enables GPCRs to promote GDP dissociation from G-proteins, which is the rate-
limiting step in GPCR signaling (Gilman 1987).  Agonist (A) binds to the receptor, also 
an equilibrium event, which may or may not be precoupled to the G-protein heterotrimer 
bound to GDP (GGDP).  Agonist bound receptor enters into equilibrium with the “ternary 
complex”, which is agonist bound to receptor coupled with a GDP-bound G-protein 
heterotrimer. This ternary complex stabilizes the receptor in its active conformation (R*) 
that promotes the dissociation of GDP from the Gα subunit in the G-protein heterotrimer.  
After GDP dissociation, GTP binds to the G in the G-protein heterotrimer causing its 
dissociation into its active components of GGTP, G and its dissociation from the 
receptor.  Full agonists are maximally able to shift the equilibrium from R to R*, partial 
agonists less so, and neutral antagonists do not affect this equilibrium.  Inverse agonists, 
however, stabilize the inactivated R state of the receptor, thereby reducing GDP/GTP 
exchange.  Additionally, constitutively active receptor spontaneously isomerizes from R 
to R* in the absence of ligand (Seifert and Wenzel-Seifert 2002).   
The ability of a cannabinoid ligand to act as a full, partial, or inverse agonist is 
frequently measured as efficacy in [
35
S]GTPS binding assays.  In these assays, a non-
hydrolysable form of GTP, in which an oxygen on the  phosphate is replaced by a 
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radioactive sulfur ([
35
S]GTPS), is incubated with cannabinoid ligands, excess GDP and 
membrane homogenates containing the CB1 receptor and G-proteins.  Receptor-activated 
G releases GDP and binds [35S]GTPS, and the accumulation of this radioactive 
complex is a measure of receptor-mediated G-protein activation in response to ligand.  
Concentration effect curves for CB1-mediated G-protein activation are generated with 
each ligand, and the Emax values of the curves are taken as measures of efficacy.  
Examples of CB1 receptor high-efficacy, full agonists include WIN 55,212-2 (WIN) and 
CP 55,940 (CP), CB1 partial agonists include 
9
-tetrahydrocannabinol (THC) and 
methanandamide (MethA) and a CB1 receptor inverse agonist is SR141716A (Breivogel 
et al. 1998; Breivogel and Childers 2000; Childers 2006).  Efficacy of partial agonists can 
also be shown indirectly by competitive antagonism; THC was first shown to be a partial 
agonist when high concentrations of THC were shown to antagonize the full effects of 
WIN when the two drugs were added together in a [
35
S]GTPS binding study in 
cerebellar membranes (Sim et al. 1996). 
 G-proteins interact with the C-terminal tail of the CB1 receptor (Nie and Lewis 
2001) and the third intracellular loop (Mukhopadhyay et al. 2000).  Demonstrated 
through the use of cannabinoid receptor intracellular domain mimicking peptides to 
disrupt specific CB1 receptor-G-protein associations, inhibitory G-protein subtypes 
interact specifically with certain regions of the CB1 receptor; Gi1 and Gi2 interact with 
third cytosolic loop of the CB1 receptor (Mukhopadhyay et al. 2000; Mukhopadhyay and 
Howlett 2001) and Gi3 and Go interact with the C-terminal tail (Mukhopadhyay et al. 
2000).  Furthermore, specific agonists have the ability to differentially activate specific 
Gi proteins.  CB1 receptors solubilized from membranes using detergent (3-[3(-
14 
 
cholamindopropyl) dimethylammonio] propanesulfonate, i.e. CHAPS) were co-
immunoprecipitated with various types of G-proteins (Gi1, Gi2, Gi3) in the absence 
of exogenously added cannabinoid ligands (Mukhopadhyay and Howlett 2005).  Addition 
of specific ligands caused the differential dissociation of the various types of G-proteins, 
demonstrating ligand-specific G-protein activation.  WIN stimulates all three Gi 
subtypes, whereas desacetyllevonantradol (DALN) stimulates Gi1 and Gi2 while 
acting as inverse agonist for Gi3, and MethA stimulates Gi3 while acting as an inverse 
agonist for Gi1 and Gi2.    SR1 acts as an inverse agonist for all three subtypes 
(Mukhopadhyay and Howlett 2005).  The synthetic analog of THC, HU210, produces 
maximal stimulation of both Gi and Go proteins, as measured by [
35
S]GTPS binding 
assays of purified G proteins reconstituted with CB1 receptors recombinantly expressed 
in Spodoptera frugiperda (Sf9) cells.  WIN maximally activated Gαi but not Gαo.  THC 
caused only partial Gαi  and Gαo activation (Glass and Northup 1999).  Overall, this 
evidence implies that different ligands can invoke various conformations of the CB1 
receptor.  Utilizing different ligands exogenously or the presence of CB1 receptor-
interacting G-proteins endogenously could change the conformation of the CB1 receptor 
to allow the promotion of differential signal transduction pathways.  In theory, selective 
pharmacological targeting of CB1 receptors could be used to promote therapeutic 
pharmacological effects while minimizing unwanted side effects induced by the CB1 
receptor, such as disruption of short-term memory and sedation (Mukhopadhyay et al. 
2002).  Moreover, if CB1 receptor G-protein coupling specificity is modulated by 
endogenous proteins, then these proteins can also be pharmacologically targeted for the 
same purpose. 
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CB1 receptors are constitutively active (Bouaboula et al. 1997; Pan et al. 1998; 
Nie and Lewis 2001), meaning that they can spontaneously shift conformation from R to 
R* in the absence of ligand.  This constitutive activity can increase basal G-protein 
activity and modulation of effector system activity, and is reversible by inverse agonists 
(Seifert and Wenzel-Seifert 2002).  Lewis and Nie (2001) found that truncation of the 
distal C-terminal tail of the CB1 receptor at amino acid 417 enhanced the constitutive 
activity of the receptor.  This raises the possibility that a protein binds to the distal C-
terminal tail that attenuates the constitutive activity of the CB1 receptor.   
A highly conserved aspartate in the second transmembrane domain, denoted 
II:14D (transmembrane domain II, amino acid position 14, aspartate (D)) (Baldwin et al. 
1997) or D164 (aspartate at CB1 amino acid position 164)  is critical to CB1 receptor 
constitutive activity.  A mutation in this aspartate abolished constitutive activity without 
disrupting agonist-mediated inhibition of Ca
+2
 channels (Nie and Lewis 2001) or 
inhibition of cAMP production.  However, disruption of this aspartate can disrupt the 
coupling of the CB1 receptor to the potentiation of inward rectifying potassium channels, 
and prevent the internalization of the receptor after exposure to agonist (Roche et al. 
1999).  When analyzing a GPCR for constitutive activity, determination of endogenous 
ligands within the study system is important to rule out endogenous ligand-mediated 
stimulation (Morisset et al. 2000).  Furthermore, CB1 receptors are constitutively 
internalized and recycled back to the cell surface, in a manner dependent on the 
constitutive activity of the receptor (Leterrier et al. 2004; Leterrier et al. 2006), although 
one group has suggested that constitutive activity may not be necessary for constitutive 
internalization of CB1 receptors (McDonald et al. 2007).  
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 In addition, GPCRs coupled to inhibitory Gi/Go proteins are affected by sodium 
concentrations (Jakobs 1979).  Sodium stabilizes the inactivated R state of the receptor 
and diminished basal G-protein activity, thus acting as an allosteric inverse agonist and 
decreasing the apparent efficacy of inverse agonists (Koski et al. 1982) (Seifert and 
Wenzel-Seifert 2002).  Specifically, sodium has been shown to decrease CB1 receptor 
agonist binding and G-protein interactions with the CB1 receptor (Devane et al. 1988; 
Kuster et al. 1993; Houston and Howlett 1998).  Additionally, an optimal sodium 
concentration is required for the coupling of CB1 receptor to adenylyl cyclase inhibition 
in specific brain regions, such as striatum.  Interestingly, inhibition of adenylyl cyclase in 
rat cerebellar second transmembrane spanning domain of GPCRs, II:14D, is responsible 
for the allosteric regulation by sodium, which was first discovered via site-directed 
mutagenesis of the 2-adrenergic receptor (Horstman et al. 1990) and has since been 
demonstrated for a plethora of other GPCRs (Horstman et al. 1990; Kong et al. 1993; 
Ceresa and Limbird 1994).  The physiological sodium concentration at this aspartate is 
unknown (Seifert and Wenzel-Seifert 2002). 
 Another hallmark of Gi/Go coupled receptor signaling is sensitivity to pertussis 
toxin (PTX), derived from Bordetella pertussis (whopping cough).  PTX ribosylates a 
cysteine in the heterotrimeric forms of  inhibitory Gi/o proteins (Locht and Antoine 
1995), thus blocking all interaction with activated R* GPCRs (Seifert and Wenzel-Seifert 
2002).  PTX is used to confirm the involvement of inhibitory Gi/o proteins in CB1 
receptor mediated downstream signals, including adenylyl cyclase inhibition (Howlett et 
al. 1986; Pacheco et al. 1994) and N-type Ca
+2
current inhibition (Guo and Ikeda 2004).  
CB1 receptor-mediated downstream signals not blocked by PTX do not involve inhibitory 
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Gi/o proteins, rather they signal through alternative CB1-mediated pathways, possibly G-
protein-coupled receptor kinases (GRKs), -arrestin, PDZ domain-containing G-proteins 
(Hall et al. 1999), or other G-proteins types, such as the signal switching to Gαs family 
members seen when CB1 receptors are stimulated concurrently with dopamine (D2) 
receptors (Glass and Felder 1997; Kearn et al. 2005). 
Once activated, CB1 receptors modulate multiple downstream signaling events, 
including inhibition of adenylyl cyclase (AC) (Howlett et al. 1986), phosphorylation of 
p42/p44 mitogen activated protein kinases (MAPK), which are also known as 
extracellular signal regulated kinases (ERK1/2) (Bouaboula et al. 1995; Derkinderen et 
al. 2001; Galve-Roperh et al. 2002), inhibition of N-type and P/Q type voltage dependent 
Ca
+2
 channels (Pan et al. 1996) (Twitchell et al. 1997), stimulation of inward rectifying 
K
+
 channel  (Mackie et al. 1995; Vasquez et al. 2003), inhibition of Na
+
 channels 
(Nicholson et al. 2003), stimulation of phospholipases C and A2 (PLC, PLA2) (Hunter et 
al. 1986), activation of c-Jun N-terminal kinase (JNK), and activation of p38 mitogen-
activated protein kinase (Rueda et al. 2000).  CB1 receptors generally inhibit AC (types 1, 
3, 5, 6 and 8), but they also have the ability to stimulate certain AC isoforms (types 2, 4, 
and 7) via G (Rhee et al. 1998). 
The modulation of downstream signaling events by activated G-proteins is usually 
accomplished through the G subunit (Clapham and Neer 1997; Offermanns 2003).  
Such is the case for MAPK (Inglese et al. 1995), N and P/Q type voltage dependent Ca
+2
 
channels (Herlitze et al. 1996),  inwardly rectifying K
+
 channel (Logothetis et al. 1987), 
and phospholipases C (Camps et al. 1992) and A2 (Jelsema and Axelrod 1987).  
Adenylyl cyclase is regulated by both Gi and G, dependent on the subtype of AC; for 
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the subtypes of AC inhibited by CB1 receptors (isoforms 1, 3, 5, 6 and 8) (Howlett et al. 
2002), type 1 is inhibited by both Gi and G, whereas types 3, 5, 6 and 8 are inhibited 
by Gi (Rhee et al. 2000; Offermanns 2003). 
1.4 Cannabinoid Receptor Regulation & Cellular Localization 
 CB1 receptors signal are regulated in their native environments not only through 
G-protein interactions, but also by modulation and trafficking of the receptors 
themselves.  Following agonist stimulation, CB1 receptors may be desensitized, 
internalized and then recycled or downregulated, similarly to other GPCRs (Figure 4) 
(Lefkowitz 1998).  Ultimately these processes lead to a reduced CB1 receptor signal, 
which could contribute to the development of tolerance (Maldonado 2002; Sim-Selley 
and Martin 2002; Sim-Selley 2003). 
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Figure 4.  G-protein coupled receptor regulation and cellular location.  Upon agonist 
stimulation, G-protein receptor kinase (GRK) phosphorylates the GPCR, impairing the 
ability of the receptor to interact with G-proteins.  This process is known as 
desensitization.  Once phosphorylated, -arrestin can bind to the GPCR, stabilizing the 
desensitized state and causing the receptor to internalize via clathrin-coated pits.  Once 
internalized, the GPCR is either degraded, otherwise known as downregulation, or 
recycled back to the cell surface following dephosphorylation in acidified endosome. 
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Upon agonist stimulation, CB1 receptors desensitize, making them less sensitive 
to subsequent stimulation.  Agonist binding causes a conformational change in the 
receptor, activates G, which recruits G-protein coupled receptor kinases (GRKs) 
(Pitcher et al. 1992), allowing G-protein coupled receptor kinase 3 (GRK3) (Hsieh et al. 
1999; Jin et al. 1999) or G-protein coupled receptor kinase (GRK2) (Kouznetsova et al. 
2002; Rubino et al. 2006) to phosphorylate serine 426 and/or 430 in the CB1 receptor C-
terminal tail (Hsieh et al. 1999; Jin et al. 1999).  GRK binding substantially impairs the 
ability of the receptor to interact with G-proteins (Pitcher et al. 1998; Reiter and 
Lefkowitz 2006).  GRK phosphorylation recruits the binding of β-arrestin, which further 
increases desensitization (Reiter and Lefkowitz 2006).  CB1 receptor desensitization can 
be seen as a decrease in the Emax of agonist stimulated [
35
S]GTPS binding in brain 
membrane homogenates, (Sim et al. 1996; Sim-Selley and Martin 2002; Selley et al. 
2004), and cannabinoid-stimulated [
35
S]GTPS autoradiography in brain slices (Sim et al. 
1995; Sim et al. 1996), both of which measure GPCR-mediated G-protein activation.  
THC treated rats (10 mg/kg/day, 21 days) subjected to [
35
S]GTPS binding and 
autoradiography experiments show a decrease in WIN-stimulated binding in all brain 
regions.  However, the magnitude of desensitization varied by region, with the largest 
decreases seen in hippocampus and cortex, followed by cerebellum, caudate-putamen, 
globus pallidus, periaqueductal gray, and the smallest decrease in substantia nigra (Sim et 
al. 1996).  In addition, the time course required for desensitization varied by brain region; 
hippocampus reached maximal desensitization follwing 7 days of THC treatment, 
whereas cerebellum took 14 days to fully desensitize, and caudate-putamen required 21 
days (Breivogel et al. 1999). 
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CB1 receptor signal is further lost upon agonist binding when the desensitized 
receptor is internalized into the cell interior (Hsieh et al. 1999; Coutts et al. 2001; Wu et 
al. 2008).  The CB1 receptor may then be degraded, a process termed downregulation, 
and can be measured as decreased binding of radioactive cannabinoid ligands in 
autoradiographic studies of brain slices (Oviedo et al. 1993; Breivogel et al. 1999; Sim-
Selley and Martin 2002)  or as decreased binding (Bmax values) in [
3
H]SR141716A 
saturation binding analyses of brain tissue homogenates (Breivogel et al. 1999; Sim-
Selley et al. 2006).  The magnitude of CB1 receptor downregulation varies from brain 
region to brain region; downregulation is greatest in cortex, cerebellum, hippocampus 
and caudate-putamen, and less downregulation is seen for substantia nigra and globus 
pallidus. (Rodriguez de Fonseca et al. 1994; Breivogel et al. 1999; Sim-Selley and Martin 
2002).  Downregulation in different brain regions is also time course dependent.  
Maximal downregulation of CB1 receptors in the rat hippocampus and cerebellum was 
achieved after 7 days of THC administration, but downregulation in the caudate/putamen 
and globus pallidus was not detectable until 21 days (Breivogel et al. 1999). 
The cause(s) of differential regional desensitization and downregulation of CB1 
receptors in the CNS remains unknown, but may be caused by differential expression of 
proteins that interact with the CB1 receptor, such as the region-specific expression of G7 
(Watson et al. 1994), differences in the formation of CB1 receptor dimers from region to 
region (Wager-Miller et al. 2002), differential changes in CB1 receptor mRNA levels in 
response to chronic cannabinoid treatment (Zhuang et al. 1998; Romero et al. 1999; Sim-
Selley et al. 2006)  or variations in other unknown and uncharacterized proteins.  
Additionally, proteins that are known to regulate CB1 receptor adaptation respond to drug 
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treatment; GRK2, GRK4, -arrestin 1 and -arrestin 2 are all upregulated by chronic 
THC treatment (Rubino et al. 2006).  These regulatory proteins may exhibit differential 
regional localization and/or respond differently to chronic THC treatment in various brain 
regions, and thus may account for differential CB1 receptor adaptation.  
Downregulation occurs when, following GRK phosphorylation, -arrestin can 
bind to the CB1 receptor, stabilizing desensitization and causing the receptor to 
internalize via clathrin-coated pits (Reiter and Lefkowitz 2006).  Once bound, -arrestin 
associates with the AP-2 complex, the heterotetrameric clathrin adaptor protein that 
targets the receptor to clathrin-coated pits (Laporte et al. 1999), and then binds directly to 
clathrin to initiate internalization (Goodman et al. 1996).  Specifically, CB1 receptors 
have been shown to rapidly internalize in AtT20 cells via clathrin coated pits, because 
sucrose pretreatment, which disrupts clathrin-coated pit formation (Heuser and Anderson 
1989), prevented CB1 receptor internalization (Hsieh et al. 1999).  Residues 460-463 for 
the CB1 receptor are required for -arrestin-mediated internalization (Hsieh et al. 1999; 
Daigle et al. 2008). 
Alternatively, CB1 receptors can internalize into caveolae (Keren and Sarne 2003; 
Bari et al. 2008; Wu et al. 2008), which are a specialized subclass of lipid rafts involved 
in cholesterol trafficking, endocytosis of external molecules, and regulation of several 
signal transduction pathways (Razani et al. 2002).  CB1 receptors can co-localize with 
caveolin-1, a major component of the caveolae protein coat (Bari et al. 2008).  
Interestingly, when both clathrin-dependent and caveolae-dependent internalization were 
blocked, CB1 receptors were still able to internalize, to a lesser extent, suggesting another 
23 
 
endocyctic pathway remains to be discovered (Keren and Sarne 2003).  An alternate 
endocytic pathway may be flotillins, which are a clathrin and caveolin-independent 
enodocytic pathway found in mammalian cells (Glebov et al. 2006) 
Exposure time is an important factor in determining the fate of internalized CB1 
receptors.  Once internalized, CB1 receptors are either dephosphorylated, resensitized and 
recycled back to the cell surface or targeted to the lysosomes for degradation 
(downregulated) (Reiter and Lefkowitz 2006).  Rapid recycling of the CB1 receptor 
occurs after short agonist exposures, and requires dephosphorylation by an okadaic acid-
sensitive phosphatase and endosomal acidification.  Resensitization of the receptors 
occurs more rapidly for high (WIN) vs. low (THC) endocytotic agonists, suggesting the 
CB1 receptor endocytosis is an important facilitator in the resensitization of CB1 receptors 
(Bohn 2007; Wu et al. 2008).  Long duration agonist exposure leads to downregulation 
(Hsieh et al. 1999).  In addition, shorter duration exposure to very high doses of CB1 
agonists can also lead to downregulation (Keren and Sarne 2003; Martini et al. 2007).   
G-protein-coupled receptor-associated sorting protein (GASP1) is responsible for 
sorting the CB1 receptor into the downregulation pathway, increasing the associating 
between CB1 receptors and lysosomal markers LAMP1 and LAMP2 (Martini et al. 2007).  
WIN-induced CB1 receptor downregulation is attenuated by a dominant-negative mutant 
of GASP1 (cGASP) in primary cultured rat spinal neurons.  Additionally, the dominant 
negative GASP1 mutant attenuated analgesic tolerance and CB1 receptor downregulation 
in vivo following its injection into the spinal dorsal horn of mice expressed in a 
recombinant chimeric adeno-associated virus 1/2 viron (Tappe-Theodor et al. 2007).  
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Once downregulated, new protein synthesis is required for the recovery of the CB1 
receptors to the cell surface (Hsieh et al. 1999). 
The specific agonist used to desenstitize/downregulate the CB1 receptor is another 
important factor in determining the fate of the CB1 receptor.  For instance, THC, a low 
endocytotic agonist exhibited greater desensitization than the high endocytic agonist 
WIN, as measured by inhibition of intracellular cAMP accumulation (Wu et al. 2008).  
Therefore, THC may robustly stimulate desensitization of CB1 receptors, while less 
robustly inducing their internalization.  Indeed, -arrestin 2 knockout mice show a 
selective enhancement of THC-induced behavioral effects.  -arrestin 2 knockout did not 
affect sensitivity to other CB1 agonists tested, including CP, MethA, JWH-073 and O-
1812 (Breivogel et al. 2008).  This finding suggests that THC-occupied CB1 receptors are 
strongly influenced by -arrestin 2, possibly recruiting -arrestin 2 only or more strongly 
than -arrestin 1, which may affect the processes of CB1 receptor desensitization and/or 
downregulation. 
Localization of the CB1 receptor within the plasma membrane itself may also be 
important.  Plasma membranes contain discrete regions of proteins and lipids, composed 
largely of cholesterol and sphingolipds in the outer leaflet of the lipid bilayer, termed 
lipid rafts (Barnett-Norris et al. 2005).  Many GPCRs localize to the lipid rafts, and 
agonist stimulation of these GPCRs can promote entry into, or exit from, the lipid raft 
microenvironments (Patel et al. 2008).  Importantly, many proteins associated with the 
signaling of GPCRs, such as heterotrimeric G-proteins, may be targeted to lipid rafts due 
to their lipid modifications, namely by the myrsotylation and/or palmitoylation of G 
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subunits and prenylation of G subunits (Wedegaertner et al. 1995).  Thus, lipid rafts 
may aggregate GPCRs and their signaling proteins to increase the specificity and 
efficiency of signal transduction (Moffett et al. 2000).  Lipid rafts may also serve to limit 
the signal transduction of CB1 receptors, because treatment of rat C6 glioma cells with 
the lipid raft disruptor methyl--cyclodextrin (MCD) increases the stimulation of 
[
35
S]GTPS binding by the endocannabinoid AEA and downstream signaling to AC and 
p42/p44 MAPK (Bari et al. 2005).  Thus exit or entry into lipid rafts via interactions with 
agonists, or CB1 interacting proteins, could be important modifiers of CB1 receptor 
activity. 
1.5 Proteins that Interact with the CB1 Receptor 
GPCRs do not interact exclusively with G-proteins.  Rather, GPCRs exist in 
tandem with numerous protein interacting partners, collectively termed a receptosome, 
that control processes such as ligand specificity, signal amplification, constitutive 
activity, GPCR localization, desensitization, internalization, recycling and 
downregulation (for review see (Tilakaratne and Sexton 2005)).   
In addition to Gi/Go proteins, the CB1 receptosome can contain numerous 
proteins, including Factor Associated with Neutral sphingomyelinase activation (FAN), 
involved in CB1-evoked sphingomyelin breakdown (Sanchez et al. 2001), Rab5 and Rab4 
GTPases that regulate constitutive endocytosis and recycling, respectively, (Leterrier et 
al. 2004),  GRK2 (Kouznetsova et al. 2002) and GRK3 (Jin et al. 1999), which  are 
involved in CB1 receptor desensitization, -arrestin 2, which is involved in CB1 receptor 
desensitization and internalization (Jin et al. 1999), and G-protein-coupled-receptor-
Associated Sorting Protein (GASP1), which plays a role in CB1 receptor downregulation 
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(Martini et al. 2007).  This study will examine the function of the novel and as yet 
relatively uncharacterized CB1 receptor interaction protein; Cannabinoid Receptor 
Interacting Protein 1a (CRIP1a) 
Like G-proteins, GRKs, -arrestin, and GASP1 discussed earlier, FAN interacts 
directly with the CB1 receptor.  The interaction of the CB1 receptor and FAN was 
discovered after the observation that THC induces sphingomyelin breakdown in primary 
astrocytes (Sanchez et al. 1998).  FAN interacts directly with CB1 in primary astrocytes, 
but not U373 MG astrocytoma cells, because FAN is immunoprecipitated from these 
cells with anti-CB1 antibody.  Interestingly, THC increased the binding of FAN to CB1 
receptors, an effect that was blocked by SR1.  Furthermore the role of FAN in CB1 
receptor coupled sphingomyelin breakdown was confirmed using cells expressing a 
dominant negative form of FAN, in which sphingomyelin breakdown was attenuated. 
(Sanchez et al. 2001). 
Contrariwise, Rab4 and Rab5 have not been shown to directly interact with the 
CB1 receptor, but functionally colocalize with the receptor during receptor trafficking.  
Rab GTPases organize membrane trafficking in eukaryotic cells and are associated with 
the cell membrane by hydrophobic geranylgeranyl groups that are attached to one or two 
carboxy-terminal cysteine(s).  Specifically, Rab4 and Rab5 are involved in endosomal 
fusion and endocytic recycling. (Stenmark 2009).  Dominant negative (GDP-bound) and 
dominant active (GTP bound) mutants of Rab4 and Rab5, but not Rab11, disrupt 
constitutive endocytosis and recycling of the CB1 receptor, confirming their involvement 
in these processes (Leterrier et al. 2004).  Although they do not directly interact with the 
receptor, these proteins may be considered part of the larger CB1 receptosome.  This 
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broad definition of receptosome could include other proteins that might be involved in 
the signaling and regulation of the CB1 receptor, including proteins involved in 
scaffolding, signal modulation or other GPCRs (e.g. CB1-GPCR heterodimers), and are 
too numerous for discussion here. 
A common protein-protein interaction motif between GPCR interacting proteins 
is the PDZ domain.  The acronym „PDZ‟ is derived from the first three proteins in which 
these motifs were identified (PSD-95, Disc large protein and ZO-1) (Tilakaratne and 
Sexton 2005).  The vast majority of PDZ-containing proteins are associated with the 
plasma membrane.  In addition, multiple copies of the PDZ domains commonly occur 
within a single polypeptide chain (Jelen et al. 2003).  These ubiquitous protein interaction 
modules are commonly found in proteins involved in receptor trafficking, receptor 
anchoring/stabilization, scaffolding for assembly of signaling molecules, and modulation 
of receptor ligand specificity (Tilakaratne and Sexton 2005).  An example of a PDZ 
containing protein is spinophilin, which contains one PDZ domain and is known to 
interact with the D2 dopamine receptor (Smith et al. 1999).  In addition, spinophilin is 
known to interact with other protein binding partners, including other GPCRs, 
cytoskeletal and cell adhesion molecules, ion channels and enzymes.  The function of 
spinophilin has not been fully elucidated, but is proposed to provide a link between 
GPCRs and mitogenic signaling events, as well as regulate synaptic plasticity, spine 
morphology, and neuronal migration (Sarrouilhe et al. 2006). 
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1.6 Cannabinoid Receptor Interacting protein (CRIP1a)  
The discovery that the truncation of the distal C-terminal tail of the CB1 receptor 
enhanced the constitutive activity of the CB1 receptor (Nie and Lewis 2001) lead to a 
search for a protein that binds to the CB1 receptor C-terminus and inhibits the constitutive 
activity of the CB1 receptor.  Two novel proteins, coined cannabinoid receptor interacting 
proteins, (CRIP1a & CRIP1b) were recently discovered via yeast two-hybrid screening of a 
human brain cDNA library using the last 55 amino acids of the C-terminal tail of the CB1 
receptor (amino acids 418-472) as bait (Niehaus et al. 2007).    
A CB1 receptor interacting gene was found on human chromosome 22 that 
alternatively splices to form CRIP1a (exons 1, 2 and 3a) and CRIP1b (exons 1, 2, and 3b), 
which are 164 and 128 amino acids, respectively.  The GenBank accession numbers for 
the nucleotide sequences of CRIP1a and CRIP1b are AY883936 and AY144596, 
respectively.  The role of CRIP1b is unclear; it is found only in primates and its effects on 
CB1 receptor function remain undiscovered.  However, CRIP1a appears to decrease the 
constitutive activity of the CB1 receptor. 
The region of the CB1 receptor required for CRIP interaction was determined 
using a yeast two-hybrid screening of various CB1 receptor C-terminal tail mutants as 
bait and CRIP1b as prey (Figure 6). The last nine amino acids of the CB1 receptor were 
required for CRIP1b interaction.  CRIP did not interact with either the desensitization (aa 
419-438) or internalization (aa 460-463) regions of the CB1 receptor.  Furthermore, 
Western blot analysis of in vitro binding assays confirmed CRIP1a/CB1 interaction, as 
bacterially expressed CRIP1a bound specifically to immobilized GST-CB1 C-terminal tail 
and not to the negative control, GST. 
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In vivo interaction of CRIP1a and the CB1 receptor was confirmed using co-
immunoprecipitation of CRIP1a with the CB1 receptor from rat brain homogenates.  
CRIP1a was highly expressed in mouse brain homogenates, and also detectable in heart, 
lung and intestine via Western blot analysis, as well as in mouse brain and cerebellar 
homogenates.  Confocal microscopy of cDNA microinjected rat superior cervical 
ganglion (SCG) neurons found that CRIP1a, CRIP1b and the CB1 receptor are enriched 
near the plasma membrane and overlap in orthogonal perspectives. 
Comparative genomic analyses indicate that CRIP1a is conserved throughout the 
vertebrates.  CRIP1a contains no transmembrane domains, as determined by hydropathy 
analysis, but does contain a predicted palmyitoylation site, which may aid its association 
with the plasma membrane.  The C-terminal tail of CRIP1a contains a predicted PDZ 
Class I ligand, which could allow it to interact with PDZ-containing G-proteins.  This 
finding suggests that CRIP1a, like many other proteins that interact with PDZ modules, 
may be important for regulating GPCR signaling, scaffolding or trafficking. 
Electrophysiological voltage-step protocol of calcium current recordings in rat 
SCG neurons microinjected with cDNA encoding the CB1 receptor, with and without co-
microinjection of cDNA encoding CRIP1a, showed that CRIP1a attenuated the constitutive 
CB1-mediated inhibition of calcium channels, as revealed by an elimination of the inverse 
agonist activity of SR1 (Figure 7) .  However, the CB1-receptor mediated decrease in 
calcium current elicited by the CB1 agonist WIN was unaffected by co-expression of 
CRIP1a (Niehaus et al. 2007).   
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Figure 6.  CB1 receptor interaction with CRIP requires the last nine amino acids of the 
CB1 C-terminal tail.  Desensitization (D) and internalization (I) regions of the CB1 
receptor are depicted as boxes.  Numbers indicate the amino acids residues of the rat (r) 
CB1 receptor used as bait in yeast two-hybrid screening.  Reprinted from Niehaus et al. 
(2007). 
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Only one other study has examined CRIP1a; Ludanyi et. al. (2008) postulated that 
endocannabinoid signaling has an important protective role against pathologic neuronal 
excitability.  To address this hypothesis, they utilized quantitative PCR measurements to 
evaluate mRNA levels of CB1 receptor related molecular elements in epileptic versus 
healthy postmortem human hippocampal tissue.  Human sclerotic hippocampi show a 
reduction in CRIP1a gene expression in tandem with reduction in CB1 receptor 
expression, suggesting that downregulation of the CB 1 receptor, in tandem with CRIP1a 
may facilitate the harmful effects of increased neuronal excitability (Ludanyi et al. 2008). 
The known effects of CRIP1a on activity modulated by the CB1 receptor are 
limited (Table 1).  According to Neihaus et al. (2007), CRIP1a does not affect CB1 
receptor expression, but does inhibit the constitutive inhibition of Ca
+2
 channels by the 
CB1 receptor without affecting agonist-induced inhibition of this effector.  This 
dissertation further examines the effect of CRIP1a on constitutive and agonist-mediated 
CB1 receptor function using human embryonic kidney (HEK) cells stably transfected 
with the human CB1 (hCB1 HEK) compared to cells containing a stable co-transfection of 
CRIP1a (hCB1-HEK CRIP1a).  Several CRIP1a effects will be examined (Figure 8), 
including effects of CRIP1a on ligand specific CB1-receptor mediated G-protein 
activation, constitutive activity of the CB1 receptor, CB1 receptor desensitization and 
downregulation, downstream signaling events, and cell type specificity of effects.  In 
addition, the stoichiometric relationship of CRIP1a to the CB1 receptor in cell and animal 
models will be examined. 
 I hypothesize that CRIP1a will attenuate constitutive CB1 receptor-mediated G-
protein activation, thus explaining the effects on downstream signaling by Neihaus et al. 
32 
 
(2007).  In addition, I expect to see a similar inhibition of CB1 receptor constitutive 
activity on other downstream signaling events, including the constitutive inhibition of 
adenylyl cylase and constitutive phosphorylation of ERK 1/2.  However, I do not expect 
CRIP1a to modulate ligand stimulated effects of the CB1 receptor at the G-protein or at 
the downstream effector level.  Additionally, because CRIP1a binds to the C-terminal tail 
of the CB1 receptor, where proteins that affect CB1 receptor trafficking also bind, it is 
possible that CRIP1a will modulate ligand-induced desensitization and downregulation of 
the CB1 receptor.  However, as the CRIP1a binding site does not directly overlap with the 
CB1 C-terminal tail region specifically required for desensitization or downregulation, 
there may be no effect.  In addition, I expect CRIP1a to be upregulated in response to 
chronic cannabinoid administration in the whole animal, as seen with other CB1 receptor 
interacting proteins such as GRKs and β-arrestins.  My overall hypothesis is that CRIP1a 
is the member of the CB1 receptosome that determines the constitutive activation of the 
CB1 receptor. 
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Figure 7.  CRIP1a decreases CB1 receptor-mediated tonic inhibition of voltage-gated Ca
+2
 
channels.  Panel a, top, voltage-step protocol used to elicit Ca
+2
 current.  Bottom, 
superimposed Ca
+2
 current traces perfusion of control solution (middle trace), 1 M WIN 
(top trace) or 1 M SR1 (bottom trace) for a representative SCG neuron expressing CB1 
receptor.  Panel b. Ca
+2
 current amplitude from a SCG neuron expressing CB1 receptor 
plotted over time course of a representative experiment.  Application of the CB1 agonist 
WIN decreased Ca
+2
 current, whereas the CB1 inverse agonist increased Ca
+2
 current.  
Panel c. top, voltage step protocol used to elicit Ca
+2
 current traces during perfusion of 
control solution (middle trace), WIN (top trace) or SR1 (bottom trace) for a 
representative neuron co-expressing CB1 receptor and CRIP1a.  Panel d. Ca
+2
 current 
amplitude from a SCG neuron co-expressing CB1 and CRIP1a plotted over the time 
course for a representative experiment.  Application of the CB1 agonist WIN decreased 
Ca
+2
 current; however, the ability of the CB1 agonist to increase Ca
+2
 current was 
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impaired.  Panel e, the ability of the CB1 agonist WIN to inhibit Ca
+2
 current is 
unaffected by CRIP1a.  Panel f, CB1-mediated enhancement of Ca
+2
 current by inverse 
agonist SR1 is significantly attenuated by CRIP1a (* p < 0.05).  Scale bars in panels a and 
c, 500 pA, 25 ms. 
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Figure 8.  CRIP1a effects to be examined in this dissertation.  This study will address the 
effects of CRIP1a on the constitutive activity of the CB1 receptor, on acute ligand-specific 
effects on CB1 receptor mediated G-protein activation, on CB1 receptor desensitization 
and downregulation in response to prolonged agonist treatment, and on CB1 receptor 
downstream signaling to effectors.  Additionally, this study will examine the 
stoichiometric relationship between CRIP1a and the CB1 receptor in CB1 receptor 
expressing cells and rat cerebellum. 
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Table 1.  Summary of the effects of CRIP1a on CB1 receptor modulated activity.  Prior to 
this dissertation, known effects of CRIP1a are listed.  References: (1) Neihaus et al. 
(2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CRIP1a Effects? Constitutive  Agonist-Mediated  
CB1 Receptor 
Expression 
No (1) None apparent. 
G-protein Activation ? ? 
Receptor 
Desensitization 
None apparent. ? 
Receptor 
Downregulation 
None apparent. ? 
Ca+2 Channel 
Inhibition 
Yes (1) No (1) 
Adenylyl Cyclase 
Inhibition 
? ? 
ERK 1/2 ? ? 
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Chapter 2.  Methodology 
 
2.1 Chemicals.   
[
35
S]GTPS (1150-1300 Ci/mmol) was obtained from PerkineElmer Life and 
Analytical Sciences (Whaltman, MA).  [
3
H]SR141716A (44.0 Ci/mmol) was purchased 
from GE Healthcare (Buckinghamshire, UK).  WIN 55,212-2 (dissolved in ethanol), 
GDP (H2O), pertussis toxin (H2O) and bovine serum albumin (BSA) were purchased 
from Sigma-Aldrich (St. Louis, MO).  THC (ethanol), CP 55,940 (ethanol), and 
SR141716A (ethanol) were provided by the Drug Supply Program of the National 
Institute of Drug Abuse (NIDA, Rockville, MD).  Methananamide (ethanol) was 
purchased from Cayman Chemical (Ann Arbor, MI).  Levonanatradol (ethanol), HU210 
(H2O) and Noladin Ether (ethanol) were supplied by the Department of Pharmacology & 
Toxicology (Virginia Commonwealth University, Richmond, VA) via the NIDA Drug 
Supply Program.  GST-tagged CRIP1a construct in pGEX vector was provided by Dr. 
Kathleen Wallis (Medical College of Georgia, GA).  CRIP1a antisera 077.4 was provided 
by Dr. Maurice Elphick (Queen Mary, University of London).  Licor Odyssey infrared 
dye secondary antibodies were purchased from Li-Cor Biosciences (Lincoln, NE).  
Alpha-tubulin antibody and phosphorylated ERK 1/2 antibody was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA).  ERK 1 antibody was purchased from Chemicon 
(Billerica, MA).  All other reagent grade chemicals were purchased from Sigma-Aldrich 
(St. Louis, MO).   
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2.2 Cell culture.   
Human embryonic kidney (HEK 293) cells stably expressing the human CB1 
receptor (hCB1-HEK) were cultured in Dulbecco‟s Modified Eagle Medium, 1x high 
glucose (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin 
(P/S), 0.25 mg/ml Geneticin (G418) and 15mM HEPES.  hCB1-HEK cells stably co-
transfected with CRIP1a  (hCB1-HEK-CRIP1a) were cultured in the same media with the 
addition of 0.1 mg/ml zeocin.  Both cell lines were provided by Dr. Deborah Lewis 
(formerly of the Medical College of Georgia).  Dr. Mary Abood (Temple University) 
created the hCB1-HEK cell line. 
Chinese hamster ovary (CHO) cells stably expressing the mouse CB1 receptor 
(mCB1-CHO) were cultured in Dulbecco‟s Modified Eagle Medium: Nutrient Mixture F-
12 (DMEM/F12) containing 10% FBS, 1% P/S, and 0.25 mg/ml Hygromycin B. mCB1-
CHO stably co-transfected with CRIP1a (CB1-CHO-CRIP1a) were cultured in the same 
media with the addition of 1 mg/ml G418.  mCB1-CHO cells were provided by Dr. Billy 
R. Martin (Virginia Commonwealth University). 
2.3 Cell Culture Drug Treatment 
 Cells were grown to greater than 95% confluency, except where otherwise 
indicated.  Appropriate concentrations of drugs were added to drug treatment media 
(DMEM, 1% FBS, 1% P/S) and sterile filtered.  Drug treatment media was added to cells 
and incubated for the appropriate time period.  To terminate drug treatments, cells were 
rinsed twice for 2 min with warm rinse media (DMEM, 1% FBS), and harvested, as in 
section 2.5, for use in assay.  
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2.4 Cell Transfection 
 Cells were transfected at 50-80% confluency.  Plasmid DNA was added to 
DMEM media and Plus Reagent (Invitrogen) in the following ratio:  per 1 g DNA, use 
60 l DMEM and 10 l Plus reagent, and incubated at room temperature (RT) for 15 
min.   DNA/Plus Reagent mixture was then combined with an equal volume mixture of 
Lipofectamine (Invitrogen) in the ratio of 2.5 l Lipofectamine per 1 g DNA and 
incubated for 15 min at RT.  Cells were rinsed 2x with DMEM, and covered with DMEM 
at the transfection medium volume recommended by the manufacturer (Invitrogen).  The 
DNA complex was added and the cells incubated for 4-6 hours.  Media were removed 
and replaced with complete culture media specific to the untransfected cell type.  
Transiently transfected cells were harvested and used after 48 hours.  
 For stable CRIP1a cell transfection, cells were trypsinized and incubated with 
increasing doses of selection antibiotic known as a „kill curve‟.  After one week, the 
concentration of selection antibiotic in which the cells were 50% confluent was the 
concentration used for all complete cell media preparations.  The 50% confluent cells 
were grown to 100% confluency.  Cells were typsinized and plated in 96-well plates at a 
density of 1 cell for every 3 wells, insuring that each colony was grown from a single 
cell.  Each week the colonies with surviving cells were moved into larger plates (24 well 
plate, 6 well plate, 10 cm dish).  The colonies were then harvested and stored for use in 
assays.  Cells were screened via immunoblot (see section 2.8) for CRIP1a expression and 
[
3
H]SR141716A saturation analysis (see section 2.9) for CB1 receptor expression.  The 
colony in which CRIP1a expression was the highest and had a CB1 receptor level most 
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similar to the CB1-CHO cells without CRIP1a transfection was selected and cultured for 
future experiments. 
2.5 Membrane Homogenate Preparation.   
Cells were harvested in PBS + 0.4% (w, v) EDTA or scraped and centrifuged at 
1000 x g for 10 min to remove media.  Cells were homogenized in ice-cold assay buffer 
(50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, 100 mM, pH 7.4), centrifuged at 
50,000 g for 10 min, and protein content was determined by the Bradford method 
(Bradford 1976). 
2.6 Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry 
(LC-ESI-MS-MS) Analysis of Endocannabinoids. 
The endocannabinoids, arachidonoyl ethanolamide (AEA) and 2-arachidonoyl 
glycerol (2-AG) were measured using a method modified from Di Marzo et al. (Di Marzo 
et al. 2000).  Briefly, 1 nmol of AEA-d8 and 2 nmol 2AG-d8 as deuterated internal 
standards were added to each sample.  The endocannabinoids were extracted from the 
samples with 3 volumes chloroform/methanol (2/1, v,v) and a 0.73% (w,v) sodium 
chloride mixture.  The chloroform was collected and evaporated to dryness with nitrogen. 
The extracts were reconstituted with 100 L methanol and placed in autosample vials for 
LC-ESI-MS-MS analysis. The AEA and 2-AG were separated and detected using a 
Shumadzu SCL HPLC system (Kyoto, Japan) with a Discovery® HS C18 Column 15cm 
x 2.1mm, 3m (Supelco: Bellefonte, PA) kept at 40°C and an Applied Bio systems 3200 
Q trap with a turbo V source for TurbolonSpray (Ontario, Canada) run in multiple 
reaction monitoring (MRM) mode. The mobile phase was 10 % water with 1g/L 
ammonium acetate and 0.1% (v,v) formic acid, and 90% (v,v) methanol with 1 g/L 
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ammonium acetate and 0.1% (v,v) formic acid    The flow rate was 0.3 mL/min and total 
run time was 10.00 min. The injection volume was 20 L and the auto sampler 
temperature was set at 5°C. The following transition ions for AEA, AEA-d8, 2-AG and 
2-AG-d8 were monitored: 348 > 62, 356 > 62, 387 > 96 and 379 > 287 m/z, respectively.  
The standard curves for the samples were 0.039 – 1.25 pmol AEA and 0.063- 2.0 nmol 2-
AG.  The limit of detection and limit of quantification were set at 0.039 pmol for AEA 
and 0.063 nmol for 2-AG. 
2.7 CRIP1a Generation, Purification, and Determination of Stoichiometry. 
Glutathione-S-transferase (GST)-tagged CRIP1a vector (GST tag-thrombin 
cleavage site-CRIP1a) was provided in pGEX-4T-1 vector (GE Healthcare, Piscataway, 
NJ), cloned into the BAM HI and XHO sites of the vector.   Plasmid DNA containing 
GST-tagged CRIP1a was transformed into E. coli BL21-DE3 competent cells.  E. coli 
were grown to OD(600) = 0.6 from a single colony, and then GST-tagged CRIP1a 
expression was induced via addition of isopropyl thiogalactoside (IPTG, 1 mM) for 6 
hours.  E. coli were collected via centrifugation (1,000 g, 10 min, 4 C) and a bacterial 
lysate produced via sonication with lysozyme (25 µg/ml).  CRIP1a induction and 
solubility tests were performed by polyacrylamide gel electrophoresis (PAGE) on harvest 
lysates (crude lysate, which was then separated into soluable and insoluable lysates) on 
10% polyacrlamide gels and stained with Coomassie blue to verify protein expression.  
GST-tagged CRIP1a was isolated from bacterial lysate using a GSTrap FF column 
(Amersham Biosciences, Piscataway, NJ) according to the manufacturer‟s instruction.  
Briefly, the column was equilibrated with binding buffer (0.1 M phosphate buffered 
saline, PBS), bacterial lysate was added to allow GST-CRIP fusion, the column was 
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washed (PBS), and the GST tag was cleaved via thrombin (500 units in 0.5 ml PBS).  
Following elution with PBS, the eluate contained protein and thrombin.  The thrombin 
was subsequently removed by HiTrap Benzamidine column purification according the 
manufacturer‟s instruction.  Briefly, the column was equilibrated with binding buffer 
(0.05 M Tris-HCl, 0.5 M NaCl, pH 7.4).  Sample was added to the column and eluted 
with binding buffer.  Eluates were collected and pooled.  CRIP1a pools and a BSA protein 
concentration curve were subject to PAGE using 15% polyacrylamide gels, and 
visualized by Coomassie blue stain.  Stained gel images were captured via ImageJ, and 
CRIP1a concentration was determined by subsequent linear regression analysis (Windows 
Excel). CRIP1a concentration curves were then generated in tandem with hCB1-HEK ( 
CRIP1a) or mCB1-CHO ( CRIP1a) cell membrane preparations or mouse cerebellum to 
determine CRIP1a concentration via immunoblot analysis on 15% polyacrylamide gels, 
visualized by the Licor Odyssey system.  From this data, the relationship between CRIP1a 
concentration in the cells and CB1 receptor levels, determined by [
3
H]SR141716A 
saturation binding, was calculated. 
2.8 Mouse THC Treatment 
 Male ICR mice were housed in an animal care facility maintained at 22  2 C on 
a 12 hour light/dark cycle.  Food and water were available ad libitum.  All experiments 
were conducted according to the guidelines established by the Institutional Animal Care 
and Use Committee of Virginia Commonwealth University Medical Center.  THC was 
dissolved in a 1:1:18 solution of ethanol, castor oil 40 mole ethoxylate (Emulphor) and 
saline.  Mice received subcutaneous injections of THC or vehicle twice daily (7:00 am 
and 3:00 pm) for 6.5 days.  Mice were injected with 10 mg/kg THC that was increased 
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every other day to 30 and 60 mg/kg THC, respectively.  Twenty-four hours after final 
injection, mice were sacrificed and decapitated.  Hippocampi were harvested from brains 
and were immediately frozen in isopentane at -30 C and stored at -80 C.  
2.9 Immunoblotting.  
Samples (70 g) of cell membrane homogenates were added to sample buffer (1 
M TRIS, 20% SDS, 1 M DTT, 60% sucrose, bromophenol blue) and boiled for 10 min.   
Samples were loaded into 15% SDS polyacrylamide gels, and electrophoresis was 
conducted at 120 V for 1.5 hours.  Proteins were electrophorectically transferred to 
polyvinylidene difluoride (PVDF) membranes at 70 V for 70 min.  Blots were blocked 
for 1 hour at room temperature (RT) with 5% (w/v) nonfat dry milk and then rinsed with 
TRIS buffered saline with 0.1% (v/v) Tween-20 (TBST).  Primary antibody (anti-CRIP1a 
antisera 077.4 (rabbit), 1:500) was incubated overnight at 4 C, followed by TBST rinse.  
Secondary antibody (Licor goat anti-rabbit 800 CW IR dye, 1:5,000) was then incubated 
at RT for 1 hr, followed by TBST rinse.  Blots were visualized with the Licor Odyssey 
system. 
2.10 [
3
H]SR141716A Binding.   
Saturation analysis of [
3
H]SR141716A ([
3
H]SR1) binding was performed by 
incubating 30 g of membrane protein with 0.5-10 nM [3H]SR1 in TME (50 mM TRIS, 3 
mM MgCl2, 0.2 mM EGTA) with 0.5% (w/v) BSA, in a total volume of 0.5 ml  5 M 
unlabeled SR1 to determine non-specific binding.  The assay was incubated for 90 min at 
30 C and terminated by vacuum filtration through GF/B glass fiber filters that were 
presoaked in Tris buffer containing 0.5% (w/v) BSA.  Bound radioactivity was 
determined using liquid scintillation spectrophotometry at 45% efficiency for [
3
H]. 
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2.11 [
35
S]GTPS Binding.   
Cell membrane preparations (10 g protein) were incubated with various drugs, 
100 mM NaCl, 0.1 % BSA, 10 M GDP and 0.1 nM [35S]GTPS in TME, 0.5 ml total 
volume, for 2 hr at 30 C.  In some experiments, 100 mM NaCl was replaced by varying 
concentrations of NaCl.  Basal binding was assessed in the absence of agonist, and 
nonspecific binding was measured with 10 M unlabeled GTPS.  The reaction was 
terminated by vacuum filtration through GF/B glass fiber filters.  Bound radioactivity 
was determined by liquid scintillation spectrophotometry at 95% efficiency for [
35
S].  
2.12 [
3
H]cAMP Whole Cell Assay 
 Cells were seeded on 24-well plates the previous evening to reach 100% 
confluency on day of assay.  Cells were treated with phosphodiesterase inhibitor mix (1 
M HEPES, 10 mM RO 20-1724, 100 mM IBMX, 100 mg/ml BSA in DMEM) for 30 min 
at 37 C.  Cells were then incubated in the presence of 10 µM forskolin, with and without 
drugs, for 8 min, in a total reaction volume of 200 µl.  Following drug treatment, cells 
were placed on ice and drug-containing media removed to terminate the reaction.  Cells 
were lysed with 3% perchloric acid for 30 min, and neutralized with 15% potassium 
bicarbonate.   
Cell lysate supernatant was assayed for cAMP formation using the Liquid Phase 
Cyclic AMP radioassay (Diagnostic Products Corporation), which determines cAMP 
concentration through competitive displacement of labeled versus unlabeled cAMP 
binding to a cAMP binding protein, according to the manufacturer‟s instruction.  Briefly, 
cell supernatant or cAMP standards are combined with [
3
H]cAMP and cAMP binding 
protein in a TRIS-EDTA buffer and incubated on ice for 90 min.  A blank (no cells), cell 
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blank (with cells), and total binding were assayed in the absence of cAMP binding 
protein.  Unbound cAMP was removed through the addition and subsequent 
centrifugation (15,000 g, 10 min, 4 C) of 100 ml of a charcoal/dextran suspension.  
Radioactivity of the supernatant was determined using liquid scintillation 
spectrophotometry at 45% efficiency for [
3
H].  A log transformation calibration curve of 
radioactivity versus standards was generated on Microsoft Excel from which unknown 
cAMP concentrations were determined. 
2.13 MAP Kinase Assay 
 Cells were seeded on 6 well plates the previous evening to reach 100% 
confluency on the day of assay.  Cells were serum starved (no FBS) for 6 hours prior to 
drug treatment.  Cells were then incubated for 8 min with either WIN (2 µM), THC (3 
µM), SR1 (0.2 µM) or vehicle in a reaction volume of 1 ml.  Following drug treatment, 
cells were placed on ice to terminate the reaction and treated with 200 µl cell lysis buffer 
(0.5% NP40, 1% Triton X-100, 20 mM Tris-HCl, 135 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1 mM NaF, 1 mM PMSF, 1 mM Na Vandate, and 1:1000 aprotonin) for 15 min.  
Cell lysates were centrifuged for 15 min at 13,000 rpm at 4 C.  The protein 
concentration of the resultant membrane preparations was determined via Bradford assay.  
Membrane preparations were subject to immunblot analysis of pERK 1/2 and ERK 1/2 
levels as described in Methods 2.9.  Membrane preparations of hCB1-HEK cells 
(CRIP1a transfection) (50 g) were probed using phosphorylated ERK 1/2 antibody 
(1:200 Santa Cruz) and ERK 1 antibody for loading control (1:250, Chemicon).     
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2.14 Data Analysis.   
Unless otherwise noted, all binding data are reported as mean values ± standard 
error of the mean (SEM) of at least three independent experiments that were each 
performed in duplicate ([
3
H]SR141716A) or triplicate ([
35
S]GTPS).  Data were analyzed 
using Graph Pad Prism v4.0c software.  Bmax, KD, Emax and EC50, values were determined 
by non-linear regression analysis.  Non-linear regression was used to fit the data to the 
following equation:  y = (Bmax)(L)/(KD + L) where y is equal to the amount of 
[
3
H]SR141716A or [
35
S]GTPS bound at receptor ligand concentration L.  Emax and EC50 
was substituted for Bmax and KD respectively where appropriate.  Bmax and Emax is the 
amount of [
3
H]SR141716A and [
35
S]GTPS bound at maximally effective concentrations 
of receptor ligand, respectively.  KD and EC50 values are the concentration of receptor 
ligand producing half maximal binding of [
3
H]SR141716A and modulation of 
[
35
S]GTPS binding, respectively.   Basal binding is determined in the absence of ligand.  
Net stimulated binding is defined as agonist-stimulated minus basal binding.  Percentage 
of stimulation is defined as (net stimulated binding/basal binding) x 100%.   
Measurements of cAMP levels and MAPK activity were the results of at least 3 
independent experiments.  cAMP levels were measured in duplicate in each experiment.  
Data are reported as percentage of control, which is defined as (ligand modulated 
value/vehicle value) x 100%. 
Significance was determined using ANOVA and the post-hoc Newman-Keuls 
Multiple Comparison Test for comparison of three or more conditions or by students t-
test for comparison of two conditions.  Two way ANOVA and the post-hoc Bonferroni 
Test was used in experiments examining the effects of CRIP1a on CB1 receptor function 
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in conjunction with NaCl effects, and on CB1 receptor desensitization.  Results were 
considered statistically significant when the p value ≤ 0.05.  
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Chapter 3.  Results 
 
3.1 CB1 Receptor Expression in hCB1 HEK, hCB1 HEK-CRIP1a Cell Lines and Rat 
Cerebellum. 
Previous studies have shown that CRIP1a localizes to the cell membrane and 
interacts with the C-terminal tail of CB1 receptors, without affecting CB1 receptor 
expression levels (see Introduction 1.6).  Initial experiments were performed to confirm 
that lack of effect of CRIP1a on CB1 receptor levels.  Human embryonic kidney cells 
(HEK) stably transfected with the human CB1 receptor (hCB1-HEK) cells were created 
by Dr. Mary Abood (Temple University).  hCB1-HEK with a stable co-transfection of 
CRIP1a  (hCB1-HEK-CRIP1a) were co-transfected and provided by Dr. Deborah Lewis 
(formerly of the Medical College of Georgia).   
 To determine whether the stable co-expression of CRIP1a affected CB1 receptor 
expression levels, [
3
H]SR141716A saturation binding analyses were performed in hCB1-
HEK and hCB1-HEK-CRIP1a cells (Table 2).  There were no statistically significant 
differences between hCB1-HEK, with and without CRIP1a co-expression with regard to 
CB1 receptor number (Bmax = 1.64  0.29 pmol/mg in cells without CRIP1a versus 1.51  
0.30 pmol/mg in cells with CRIP1a) or the equilibrium dissociation constant, (KD = 3.02  
1.59 nM in cells without CRIP1a versus 3.82  1.34 nM in cells with CRIP1a), according 
to students t-test (signficance reached at p < 0.05).   
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Bmax 
(pmol/mg) 
KD 
(nM) 
hCB1-HEK 1.64  0.298  3.02 ± 1.59 
hCB1-HEK-CRIP1a  1.51  0.308  3.82 ± 1.34 
Rat Cerebellum 3.63 ± 0.372 0.452 ± .077 
 
 
Table 2.  [
3
H]SR141716A saturation analysis of hCB1-HEK cells, with and without 
CRIP1a co-expression, and rat cerebellum.  Data are mean values  SEM (n=6).  Bmax 
values represent total cell membrane receptor levels.  No significant differences between 
the two hCB1-HEK cell types were observed.  KD values represent the reciprocal of the 
affinity of [
3
H]SR141716A for the receptor.  No significant effect of CRIP1a on the 
affinity of [
3
H]SR141716A binding was observed. 
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In addition, CB1 expression levels were determined in rat cerebellum, for later 
stoichiometric comparison to the hCB1-HEK ( CRIP1a) cell lines.  Rat cerebellum 
expressed CB1 receptors at a Bmax value of 3.63 ± 0.372 pmol/mg. 
3.2 CB1 Receptor Expression Relative to Cell Confluency in hCB1-HEK ( CRIP1a) 
Cell Lines. 
 The level of cell confluency can affect the expression level of cell surface 
receptors, which might be modulated by CRIP1a.  To determine whether cell confluency 
affected the expression of stably transfected CB1 receptor in the hCB1-HEK ( CRIP1a) 
cell lines, cells were grown to low (50%), high (95%), and ultra-confluence (100+ %) and 
assayed for CB1 receptor expression using saturation analysis of [
3
H]SR141716A binding 
(Figure 9).  High and ultra-confluence did not affect CB1 receptor expression in hCB1-
HEK with and without CRIP1a transfection.  However, low confluency significantly 
decreased CB 1 receptor expression in hCB1-HEK cells compared to hCB1-HEK-CRIP1a 
cells (ANOVA, Newman Keuls Multiple Comparison post-hoc test).  hCB1-HEK cells at 
50% confluency expressed a Bmax value of 0.90  0.29 pmol/mg compared to a Bmax 
value of 1.43  0.29 and 1.64  0.29 pmol/mg for high and ultra-confluency, respectively.   
Low confluency did not affect CB1 receptor expression in hCB1-HEK-CRIP1a cells, with 
a Bmax value of 1.68 ± 0.17 pmol/mg compared to 1.63  0.26 and 1.51  0.30 pmol/mg 
for high and ultra-confluency, respectively.  In all subsequent radioligand binding 
experiments, cells were harvested and utilized at a greater than 95% confluence. 
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Figure 9.  CB1 receptor expression relative to cell confluency in hCB1-HEK cells 
(CRIP1a co-expression).  Data are mean Bmax values from saturation analysis of 
[
3
H]SR141716A binding  SEM (n=4).  hCB1-HEK cells (CRIP1a transfection) were 
grown to low (50%), high (95%) and ultra-confluence (100+%) and subject to 
[
3
H]SR141716A.  High and ultra confluence did not affect CB1 receptor expression in 
hCB1-HEK cells (CRIP1a transfection).  Low confluency significantly decreased CB1 
receptor expression in hCB1-HEK cells compared to hCB1-HEK-CRIP1a cells.  (ANOVA, 
Newman Keuls Multiple Comparison post-hoc test, p < 0.05). 
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3.3 CRIP1a Expression and Stoichiometric Relationship of CRIP1a/CB1 in hCB1 
HEK Cell Lines ( CRIP1a co-transfection) and Mouse Cerebellum. 
 The effect of CRIP1a on CB1 receptor function is likely to be determined in part 
by the molar ratio of CRIP1a to CB1 receptor.  To determine the stoichiometric 
relationship of the CRIP1a to CB1 receptor, CRIP1a was generated and purified using 
GST-pulldown methodology.  Purified CRIP1a was used to generate CRIP1a concentration 
curves.  hCB1-HEK ( CRIP1a) membrane preparations (70 g) were compared to CRIP1a 
concentrations curves via immunoblot of 15% polyacrylamide gels and visualized by the 
Licor Odyssey system to elucidate unknown CRIP1a concentrations (Figure 10).  CRIP1a 
concentrations were determined for male mouse cerebellum in the same manner.  
Experimentally determined CRIP1a concentrations were compared to CB1 receptor 
expression (Table 2) to determine the molar stoichiometric relationship of CRIP1a/CB1 
receptors (Table 3).  In hCB1-HEK cells lacking CRIP1a transfection, the molar ratio of 
CRIP1a/CB1 is less than 1 (0.376  0.875), indicating that the CB1 receptor is in molar 
excess relative to amount of CRIP1a natively expressed in hCB1-HEK cells.  In hCB1-
HEK-CRIP1a cells, CRIP1a is in molar excess to the CB1 receptor, with a molar ratio of 
CRIP1a/CB1 receptor of 5.47  0.429.  These CRIP1a/CB1 receptor molar ratios are 
statically different (t-test, p < 0.001).  Interestingly, mouse cerebellum has a CRIP1a/CB1 
receptor molar ratio of 33.6  5.19, which indicates a molar excess of CRIP1a compared 
to the CB1 receptor, similar to the hCB1-HEK cell line, although somewhat greater in 
magnitude. 
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Figure 10.   Quantitative western blot analysis of CRIP1a concentration in hCB1-HEK 
cells (CRIP1a transfection) and rat cerebellum.  CRIP1a purified via GST-pulldown 
methodology generated a CRIP1a concentration curve.  Probed membrane preparations 
(A) hCB1-HEK cells (CRIP1a transfection) (70 g/sample) and (B) mouse cerebellum 
(100 g/sample) using anti-CRIP1a antisera 077.4 (Elphick, rabbit, 1:500) followed by 
Licor Odyssey goat anti-rabbit 800 CW IR dye (1:5,000).  Mouse cerebellum loading 
control probed using anti--tubulin (Santa Cruz Biotechnology, 1:500) followed by Licor 
Odyssey goat anti-mouse 680 IR dye (1:5,000).  Images were analyzed via Licor Odyssey 
Infrared Imaging System.  Unknown CRIP1a concentrations were calculated by linear 
regression analysis using Microsoft Excel.  Images are from a representative immunoblot 
of 3 replicates. 
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CB1 
(pmol/mg) 
CRIP1a  
(pmol/mg) 
Molar Ratio 
(CRIP1a/CB1) 
hCB1-HEK 1.64  0.298  0.564  0.131  0.376 ± 0.875 
hCB1-HEK-CRIP1a  1.51  0.308  8.20  0.643  5.47 ± 0.429
*
  
Rat Cerebellum 3.63  0.371  115  12.2  33.6 ± 5.19 
 
Table 3.  Stoichiometric molar ratio of CRIP1a/CB1 in hCB1-HEK cells (CRIP1a 
transfection) and rat cerebellum. Data are mean Bmax values from saturation analysis of 
[
3
H]SR141716A binding  SEM for CB1 receptor expression, CRIP1a concentration 
(pmol/mg) determined via immunoblot  SEM, and resulting molar ratio  SEM (n=4).   
Stable CRIP1a transfection caused a significant increase in CRIP1a expression, creating a 
significant molar excess relative to CB1 receptor expression ( 
*
 = p < 0.001 different from 
hCB1-HEK cells lacking CRIP1a transfection). 
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3.4 CRIP1a Modulation of Ligand Specific CB1 Receptor-Generated G-protein 
Activation; [
35
S]GTPS Binding in hCB1-HEK ( CRIP1a) Lines. 
 The interaction of CRIP1a with the intracellular surface of CB1 receptors could 
affect the ability of the receptor to activate G-proteins.  Indeed, Neihaus et al. (2007) 
have reported that co-expression of CRIP1a with CB1 receptors in SCG neurons decreased 
the basal activity of CB1 receptors without altering WIN-stimulated activity (see 
Introduction 1.6).  I hypothesize that the effects of CRIP1a on CB1 receptor basal activity 
downstream are generated at the level of acute G-protein activation, and that CRIP1a co-
expression will decrease constitutive CB1 receptor-mediated G-protein activation, but not 
in G-protein activation induced by agonist ligands.  Therefore, to determine the effects of 
CRIP1a on basal and agonist stimulated CB1 receptor mediated G-protein activity, 
[
35
S]GTPS binding was performed in hCB1-HEK ( CRIP1a) cells (Figure 11).  A wide 
variety of CB1 ligands were tested, including the classical phytocannabinoid THC, and its 
synthetic nantradol analog Levo, the aminoalkylindole WIN, the nonclassical bicyclic 
CP, the eicosanoid MethA (a stable analog of the endocannabinoid anandamide), the 
diarylpyrazole inverse agonist SR1, the classical synthetic cannabinoid HU210, and the 
putative endogenous cannabinoid Nol Eth.   
 In hCB1-HEK cells, Nol Eth appeared to act as a full agonist, while WIN, CP and 
HU210 also acted as high efficacy agonists.  MethA and Levo acted as high to moderate 
efficacy partial agonists, THC acted as a low efficacy partial agonist and SR1 acted as an 
inverse agonist.  Interestingly, CRIP1a co-expression reduced the apparent inverse 
agonism of SR1 (Figure 16), in agreement with Neihuas et al. (2007).  SR1 produced –
13.34  1.65% stimulation which was reduced to –7.33  1.21 in the presence of CRIP1a. 
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Figure 11.  Ligand-induced [
35
S]GTPS binding in hCB1-HEK and hCB1-HEK-CRIP1a 
cells.  The top panel shows concentration-effect curves for WIN, MethA, and Levo, the 
middle panel shows curves for CP, THC and SR1, and the bottom panel shows curves for 
HU210 and Nol Eth.  Data points are mean % stimulation  SEM (n=3).  All experiments 
were performed in the presence of 100 mM NaCl. 
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Figure 12.  Emax values for Nol Eth, HU210, WIN, CP, MethA, THC, Levo and SR1 in 
membranes from hCB1-HEK cells with and without co-expression of CRIP1a. Data are 
mean Emax values derived from the concentration-effect curves shown in Figure 11  
SEM (n=3).  Significant differences were found for the Emax values of Nol Eth, HU210, 
WIN, CP and SR1 in cells with CRIP1a co-expression compared to those without. 
*
,
**
: p < 
0.05, 0.01 different from the corresponding drug in non-CRIP1a expressing cells by 
ANOVA with post-hoc Newman-Keuls Test. 
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CRIP1a also reduced CB1 receptor-mediated G-protein activation of the high 
efficacy agonists Nol Eth, HU210, WIN and CP.  Nol Eth produced an Emax value of 
158.2  16.6% in hCB1-HEK cells, which was significantly reduced to an Emax value of 
108.1  6.7% in hCB1-HEK-CRIP1a cells.   Nol Eth produced an Emax value of 129.5  
13.9% in hCB1-HEK cells, which was significantly reduced to an Emax value of 85.6  
14.5% in hCB1-HEK-CRIP1a cells.   WIN produced an Emax value of 111.10  6.66% 
stimulation in hCB1-HEK cells, which was significantly reduced to an Emax value of 
79.47  2.46% in hCB1-HEK-CRIP1a cells.  CP stimulated hCB1-HEK cells to an Emax 
value of 100.10  9.32% which CRIP1a co-expression significantly reduced to an Emax 
value of 74.95 7.69%. 
Stimulation by MethA, Levo, and THC were unaffected by CRIP1a (Emax value of 
84.55  8.48% stimulation by MethA in hCB1-HEK cells compared to Emax value of 
80.23  8.02% in hCB1-HEK-CRIP1a).  Levo produced an Emax value of 73.28  4.07% in 
hCB1-HEK compared to an Emax value of 72.84  4.52% in hCB1-HEK CRIP1a.  THC 
produced an Emax value of 17.90  2.68% in hCB1-HEK compared to an Emax value of 
19.74  1.07 in hCB1-HEK CRIP1a.  All data were analyzed via ANOVA (p < 0.05, n = 
16, F = 84.87, R
2
 = 0.9725, and df = 17), with post-hoc Neuman Keuls Multiple 
Comparison Test post-hoc.  Significance was reached at p < 0.05.   
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3.5 The Effects of CRIP1a on Spontaneous CB1 G-protein Activation; [
35
S]GTPS 
Binding in hCB1-HEK ( CRIP1a) Cell Lines with Varying Na
+
 Levels. 
Spontaneous CB1 receptor mediated G-protein activity in hCB1-HEK cells was 
relatively small in magnitude, as determined by SR1 inhibition of [
35
S]GTPS binding 
(see Results 3.4).  Therefore, it was of interest to examine the effects of CRIP1a under 
varying conditions of spontaneous CB1 receptor activity.  I hypothesize that as 
spontaneous CB1 receptor activity increases, the ability of CRIP1a to decrease constitutive 
activity will become more pronounced.  In addition, the magnitude of attenuation of the 
net stimulatory effects of WIN on the CB1 receptor-mediated G-protein activity by 
CRIP1a is hypothesized to decrease as a function of spontaneous receptor activity, 
whereas attenuation of net SR1-inhibited G-protein activity is expected to increase as a 
function of spontaneous receptor activity.  Because Na
+
 is a negative allosteric modulator 
of spontaneous GPCR activity, the effects of CRIP1a on spontaneous CB1 receptor-
mediated G-protein activity were examined in [
35
S]GTPS binding studies with varying 
NaCl concentrations.  hCB1-HEK ( CRIP1a) cells were incubated with maximally 
effective concentrations of WIN (10 M), THC (6 M), SR1 (0.05 M) or under basal 
conditions and increasing doses of NaCl (0-175 mM). 
For hCB1-HEK cells with and without CRIP1a co-expression, increasing sodium 
concentrations lead to a decrease in overall G-protein activation for all conditions tested 
(Figure 13). 
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Figure 13.  [
35
S]GTPS binding in hCB1-HEK cells (CRIP1a co-expression) with 
varying NaCl concentrations.  Cells were incubated with maximally effective 
concentrations agonist concentrations (10 M WIN, 6 µM THC) and a maximally 
inhibiting concentration of the inverse agonist SR1 (0.5 M SR1) in the presence of 
varying concentrations of NaCl (0-150 mM). Data points are mean [
35
S]GTPS bound 
(fmol/mg)  SEM (n=5).  * indicates statistically significant difference in hCB1-HEK-
CRIP1a cells compared to identical conditions in hCB1-HEK cells via two-way ANOVA 
with post-hoc Bonferroni Test (p < 0.05). 
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Furthermore, CRIP1a co-expression decreased WIN-stimulated G-protein activation at all 
NaCl concentrations tested, similar to the earlier experiments under 100 mM NaCl 
(Figure 16).  At high NaCl concentrations (> 50 mM NaCl), THC was unaffected by 
CRIP1a co-expression, also as in earlier experiments (Figure 12).  CRIP1a significantly 
decreased GPCR- mediated G-protein activation when spontaneous CB1 activity was high 
(0, 10 & 25 mM NaCl) for all conditions tested.  Data were analyzed using two-way 
ANOVA with Bonferroni post-hoc test, which found both a significant interaction of 
CRIP1a and NaCl (p < 0.0001, DF = 7), and both CRIP1a and NaCl were a significant 
source of variation for all treatment groups (p < 0.05, DF = 7). 
Additionally, basal activity was subtracted from all the conditions and the data 
were expressed as net fmol/mg (Figure 14).  When examining net [
35
S]GTPS binding, 
the apparent CRIP1a effects on spontaneous CB1 receptor mediated G-protein activation 
at low NaCl concentrations are lost.  However, the decrease in WIN-stimulated G-protein 
activation in the presence of CRIP1a remains significant.  Data were analyzed using two-
way ANOVA with Bonferroni post-hoc test, which found a significant interaction of 
CRIP1a and NaCl in WIN treated cells (p < 0.0001, DF = 56).  NaCl was a significant 
source of variation for all treatments (p < 0.0001).  However, CRIP1a was only a 
significant source of variation for WIN treatment (p = 0.0098).  For each analysis, DF = 
7. 
Lastly, net fmol/mg data were analyzed for area under the curve (AUC) (Figure 
19).  CRIP1a co-expression significantly decreased AUC for WIN stimulated [
35
S]GTPS 
binding (10000  579 fmol/mg in hCB1-HEK versus 6920  590 fmol/mg in hCB1-HEK-
CRIP1a cells, two-way ANOVA, p < 0.001).  The presence of CRIP1a did not statistically 
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affect AUC in the presence of THC (2010  143 fmol/mg in hCB1-HEK versus 1440  
189 fmol/mg in hCB1-HEK-CRIP1a cells) or SR1 (-1840  362 fmol/mg in hCB1-HEK 
versus -1420  343 fmol/mg in hCB1-HEK-CRIP1a cells).  However, there was a trend for 
CRIP1a to decrease the apparent inverse agonism of SR1.  Data were analyzed via two-
way ANOVA, with post-hoc Bonferroni Test (df = 2, F = 9.910).  Significance was 
reached at p < 0.05. 
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Figure 14. Net-stimulated [
35
S]GTPS binding in hCB1-HEK cells (CRIP1a co-
expression) with varying NaCl concentrations.  Cells were incubated with maximally 
effective concentrations of cannabinoid ligands (10 M WIN, 6 µM THC) and a 
maximally inhibiting concentration of the inverse agonist SR1 (0.5 M SR1) in the 
presence of varying concentrations of NaCl (0-150 mM).  Data are mean net-stimulated 
fmol/mg  SEM (n=5).  * indicates statistically significant difference in hCB1-HEK-
CRIP1a cells compared to identical conditions in hCB1-HEK cells via two-way ANOVA 
with post-hoc Bonferroni Test (p < 0.05).  
 
64 
 
 
Figure 15.  Area under the curve (AUC) analysis of net-stimulated [
35
S]GTPS binding 
studies in hCB1-HEK cells (CRIP1a co-expression) with varying NaCl concentrations.  
Cells were incubated with maximally effective concentrations of cannabinoid ligands (10 
M WIN, 6 µM THC) and a maximally inhibiting concentration of the inverse agonist 
SR1 (0.5 M SR1) in the presence of varying concentrations of NaCl (0-150 mM) (see 
figure 14).  Data are mean AUC of net fmol/mg caculated from the curves shown in 
Figure 14  SEM (n=5). * indicates statistically significant difference in hCB1-HEK-
CRIP1a cells compared to identical conditions in hCB1-HEK cells (ANOVA with post-
hoc Newman-Keuls Test, p < 0.05). 
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3.6 [
35
S]GTPS in hCB1-HEK ( CRIP1a) Cell Lines with PTX Pre-treatment, with 
and without 100 mM NaCl. 
 Given that basal and agonist G-protein activity was negatively modulated by Na
+
 
concentrations, the previous results question whether CRIP1a modulates GPCR-mediated 
G-protein activity or directly affects G-proteins.  I hypothesize that CRIP1a acts 
exclusively on the CB1 receptor, to which it binds, without directly interacting with G-
proteins.  To determine the effect of CRIP1a on GPCR-specific G-protein activation 
versus non-GPCR mediated G-protein activity, [
35
S]GTPS binding was performed on 
hCB1-HEK ( CRIP1a) cells with and without pertussis toxin (PTX) pretreatment, and in 
the presence and absence of sodium (Figure 16).  Under normal 100 mM Na
+
 conditions, 
CRIP1a significantly reduced WIN stimulated [
35
S]GTPS binding, as seen in the 
previous experiments (149.7  19.2 fmol/mg in hCB1-HEK vs. 121.5  17.1 fmol/mg in 
hCB1-HEK-CRIP1a cells).  In the hCB1-HEK cells lacking CRIP1a, PTX pre-treatment 
significantly reduced GPCR-dependent G-protein activation.  Interestingly, in CRIP1a-
containing cells, there was no significant difference between cells with or without PTX 
pre-treatment under basal or SR1 inhibited conditions.  Data were analyzed via ANOVA 
( n = 12, F = 20.28, R
2
 = 0.8711), with post-hoc Neuman Keuls Multiple Comparison 
Test, significance reached at p <0.05.  
Spontaneous G-protein activity was enhanced by the lack of Na
+
; under these 
conditions CRIP1a decreased G-protein activation under all conditions tested.  
Furthermore, in CRIP1a-containing cells, there was a significant difference between G-
protein activation with and without PTX pre-treatment for all conditions tested, 
suggesting that while CRIP1a does decrease G-protein activity, it is not as effective as 
66 
 
PTX when spontaneous GPCR activity is high.  All data were analyzed via ANOVA (n = 
12, F = 70.24, R
2
 = 0.9590), with post-hoc Neuman Keuls Multiple Comparison Test, 
significance reached at p < 0.05.   
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Figure 16.  [
35
S]GTPS binding in hCB1-HEK cells (CRIP1a co-expression) with 
varying NaCl concentrations, with and without PTX pre-treatment.  NC indicates no 
CRIP1a.  Cells were incubated with maximally effective concentrations agonist 
concentrations (10 M WIN, 6 µM THC) and a maximally inhibiting concentration of the 
inverse agonist SR1 (0.5 M SR1) in the presence (top) or absence (bottom) of NaCl and 
with or without PTX pre-treatment.  Data points are averaged from at least independent 
three experiments containing measurements made in triplicate  SEM.  * indicates 
statistically significant difference in hCB1-HEK-CRIP1a cells compared to identical 
conditions in hCB1-HEK cells, # indicates statistically significant difference between no 
treatment versus PTX pre-treatment within the cell type (ANOVA with post-hoc 
Newman-Keuls Test, p < 0.05). 
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3.7 Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry 
(LC-ESI-MS-MS) Analysis of Endocannabinoids in hCB1-HEK ( CRIP1a) Cell 
Lines. 
 Basal G-protein activity in CB1 receptor expressing cells can be due in part to the 
presence of endocannabinoids or to actual spontaneous GPCR-mediated G-protein 
activity.  To determine whether endocannabinoids were present in sufficient levels to 
activate CB1 receptors, the levels of the two established endocannabinoids, AEA and 2-
AG, were measured via liquid chromatography electrospray ionization tandem mass 
spectrometry (LC-ESI-MS-MS) in hCB1-HEK ( CRIP1a) cell lines (Table 4).  For both 
cells types, 3 samples of whole cells (10 x 10
6
 cells) or membrane preparations (1,000 
g) were analyzed.  There were no detectable levels of AEA or 2-AG in whole cell or 
membrane preparations for either hCB1-HEK ( CRIP1a) cell lines. 
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 AEA (pmol) 2-AG (nmol) 
hCB1-HEK 
Whole cells (10 x 10
6
) 
None Detected None Detected 
hCB1-HEK 
Membrane prep (1,000 g)  
None Detected None Detected 
hCB1-HEK-CRIP1a 
Whole cells (10 x 10
6
) 
None Detected None Detected 
hCB1-HEK-CRIP1a 
Membrane prep (1,000 g) 
None Detected None Detected 
 
Table 4.  Endocannabinoid levels in CB1 in hCB1-HEK cells (CRIP1a co-expression).   
Liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS-
MS) was used to determine the levels of two endocannabinoids, AEA and 2-AG in whole 
cell and membrane preparations of hCB1-HEK cells (CRIP1a co-expression).  Data are 
mean values (pmol/nmol)  SEM of three independent experiments.  No AEA or 2-AG 
were detected in either cell line or either preparation type. 
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3.8 CRIP1a Effects on CB1 Receptor Desensitization; [
35
S]GTPS Binding in Drug-
treated hCB1-HEK ( CRIP1a) Cell Lines. 
The CB1 receptor C-terminus is important in the regulation of CB1 receptor 
signaling by the GRK/-arrestin pathway, as described in Introduction 1.4.  CRIP1a is 
known to interact with the CB1 receptor C-terminus and therefore could modulate the 
response of this receptor to prolonged agonist occupancy, such as desensitization or 
downregulation.  I hypothesize that CRIP1a will affect CB1 receptor desensitization; 
CRIP1a may only affect high efficacy ligand desensitization induced by WIN treatment as 
a result of reduced CB1 receptor-mediated G-protein activation, or could affect the 
desensitization induced by all full and partial agonist ligands as a result of steric 
hindrance with receptor regulatory proteins such as GRK or β-arrestin.  To determine the 
effects of CRIP1a on CB1 receptor desensitization, hCB1-HEK ( CRIP1a) cells were pre-
incubated with WIN (10 M), THC (6 M) or vehicle for 4 hours, followed by MethA-
stimulated [
35
S]GTPS binding to assess CB1 receptor function (Figure 17).  MethA was 
used to assess CB1 activation because acute stimulation of [
35
S]GTPS binding by this 
ligand was unaffected by CRIP1a (Figure 12).   
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Figure 17.  [
35
S]GTPS binding in hCB1-HEK cells (CRIP1a co-expression) following 
four hour drug pretreatment.  Cells were pre-treated with maximally effective 
concentrations of agonist (10 M WIN, 5 µM THC) or vehicle and subjected to MethA-
stimulated [
35
S]GTPS binding.  Concentration effect curves were generated for vehicle, 
WIN and THC-treated cells.  Data points are mean % stimulation  SEM (n=4). 
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Two-way ANOVA of Emax values indicate that drug pretreatment was a 
significant source of variation (df = 2, F = 73.69, significance reached at p < 0.05), 
suggesting that pretreatment with either WIN or THC caused significant desensitization 
of the CB1 receptor.  However, there was no significant effect of CRIP1a or an interaction 
between CRIP1a and drug treatment.  Similarly, as reveled by two-way ANOVA, EC50 
values were affected by drug treatment (df = 2, F = 7.418 significance reached at p < 
0.05), but there was no effect of CRIP1a nor an interaction between the two.  Therefore, 
CRIP1a did not affect cannabinoid-induced CB1 receptor desensitization. 
Subsequent 1-way ANOVA with Newman-Keuls Multiple Comparison Test 
(significance reached at p < 0.05, n = 6) revealed that both Emax and EC50 values for WIN 
and THC pre-treatment were significantly different from vehicle (Table 5), except for the 
Emax value of THC pre-treated hCB1-HEK-CRIP1a cells.  ANOVA of Emax yielded F = 
30.11 and R
2
 = 0.8931, and ANOVA of EC50 yielded F = 6.442 and R
2
 = 06823.  
Pretreatment with WIN decreased the Emax value of MethA by 66.5 % in hCB1-HEK 
cells and by 67.0 % in hCB1-HEK-CRIP1a cells compared to vehicle.  Pretreatment with 
THC decreased the Emax value of MethA by 21.9 % in hCB1-HEK cells and by 7.2 % in 
hCB1-HEK-CRIP1a cells compared to vehicle.  Pretreatment with WIN or THC resulted 
in an approximately 10-fold increase in EC50 values. 
    
The basal values of G-protein activation were unchanged by CRIP1a for all 
treatment groups (48.9  1.92 fmol/mg, 47.3  2.71 fmol/mg and 55.6  1.83 fmol/mg in 
hCB1-HEK cells for vehicle, WIN and THC treatment, respectively, and 43.9  4.21 
fmol/mg, 55.0  10.5 fmol/mg and 45.5  1.98 fmol/mg in hCB1-HEK-CRIP1a cells for 
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vehicle, WIN and THC treatment, respectively).  Data were analyzed via ANOVA, with 
post-hoc Neuman Keuls Multiple Comparison Test.  Significance was reached at p < 
0.05. 
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 Emax (% Stimulation) EC50 (μM) 
hCB1-HEK 
Vehicle Treated 
128   8.04  0.308  0.071  
hCB1-HEK 
WIN Treated 
43.1  7.07 *  5.70  2.11 *  
hCB1-HEK 
THC Treated 
100  8.55 *  3.00  0.049 *  
hCB1-HEK-CRIP1a 
Vehicle Treated 
112  5.10  0.423  0.082  
hCB1-HEK-CRIP1a 
WIN Treated 
37.0  4.73 *  4.16  0.595*  
hCB1-HEK-CRIP1a  
THC Treated 
104  7.37  5.17  1.31*  
 
Table 5.  Emax and EC50 values from concentration-effect curves of MethA-stimulated 
[
35S]GTPγS binding in hCB1-HEK cells (CRIP1a) following four hour pre-treatment 
with vehicle, WIN or THC.  Data are means values derived from the concentration-effect 
curves shown in Figure 21 ± SEM (n=4).  * indicates statistically significant difference 
from vehicle treatment within cell type via one-way ANOVA with post-hoc Newman-
Keuls Multiple Comparison Test (p < 0.05). 
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3.9 CRIP1a Effects on CB1 Receptor Downregulation; [
3
H]SR141716A Saturation 
Analysis in Drug-treated hCB1-HEK ( CRIP1a) Cell Lines. 
 Although CRIP1a did not have a significant effect on CB1 receptor desensitization, 
the CRIP1a binding site on the CB1 receptor is known to be near the binding site for 
GASP1, a protein involved in CB1 receptor downregulation (see Introduction 1.4).  
Therefore, I hypothesize that CRIP1a may be able to affect CB1 receptor downregulation 
without affecting desensitization.  To determine the effects of CRIP1a on CB1 receptor 
downregulation, hCB1-HEK ( CRIP1a) cells were pre-incubated with WIN (10 M), 
THC (6 M) or vehicle for 4 hours, followed by [3H]SR141716A saturation analysis to 
assess CB1 receptor expression (Figure 18).  
In hCB1-HEK cells, both WIN and THC caused significant downregulation of the 
CB1 receptor.  WIN pretreatment decreased the [
3
H]SR141716A Bmax value to 48.2  
7.9% of vehicle control and pretreatment with THC decreased the Bmax value to 23.6  
7.8% of vehicle control for hCB1-HEK cells.  Absolute Bmax values for vehicle, WIN and 
THC treated hCB1-HEK cells were 1.09  0.06 pmol/mg, 0.53  0.08 pmol/mg, and 0.26 
 0.08 pmol/mg, respectively.  
CRIP1a attenuated WIN-induced CB1 receptor downregulation.  WIN pretreatment 
decreased the Bmax value to 85.9  22.1% of vehicle control in hCB1-HEK-CRIP1a cells, 
which was not significantly different from control.  However, CRIP1a did not 
significantly decrease THC-induced downregulation.  The Bmax value (50.4  25.6% of 
vehicle control) in THC-treated hCB1-HEK-CRIP1a cells was not significantly different 
from the Bmax value of THC-treated hCB1-HEK cells (23.6  7.8%).  Absolute Bmax 
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values for vehicle, WIN and THC treated hCB1-HEK-CRIP1a cells were 1.28  0.22 
pmol/mg, 0.99  0.22 pmol/mg, and 0.49  0.21 pmol/mg, respectively. Data were 
analyzed via one-way ANOVA (n= 6, F = 7.493, R
2
  = 0.6408) with post-hoc Neuman 
Keuls Multiple Comparison Test.  Significance was reached at p < 0.05.  
Further analysis examined absolute Bmax and Kd values (Table 6).  In agreement 
with % vehicle data, WIN and THC caused significant downregulation of the CB1 
receptor in hCB1-HEK cells, which CRIP1a co-expression prevented in WIN pre-treated 
cells.  Furthermore, the KD values were not significantly different between vehicle and 
drug pretreated groups in either cell line, indicating effective removal of the drug 
following pretreatment. 
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Figure 18.  CB1 receptor levels in hCB1-HEK cells (CRIP1a co-expression) following 
four hour drug pretreatment.  Cells were pre-treated with maximally effective 
concentrations agonist concentrations (10 M WIN, 5 µM THC) or vehicle. Bmax 
(pmol/mg) values were obtained by [
3
H]SR141716A saturation analysis and are 
expressed as mean % of vehicle control  SEM (n=4).  * indicates statistically significant 
difference from vehicle within each cell type, # indicates statistically significant 
difference comparing two cell types with the same treatment (ANOVA with post-hoc 
Newman-Keuls Test, p < 0.05). 
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 Bmax  (pmol/mg) KD (nM) 
hCB1-HEK  
Vehicle Treated  
1.09  0.065  1.48  0.346  
hCB1-HEK 
WIN Treated 
0.531  0.089*  0.984  0.272  
hCB1-HEK 
THC Treated 
0.260  0.087*  1.12  0.997  
hCB1-HEK-CRIP1a 
Vehicle Treated 
1.28  0.227  2.93  0.675  
hCB1-HEK-CRIP1a 
WIN Treated 
0.994  0.220  3.11  1.16  
hCB1-HEK-CRIP1a  
THC Treated  
0.499  0.214*  2.42  1.24  
 
Table 6.  Bmax and KD values from [
3
H]SR141716A binding studies using hCB1-HEK 
cells (CRIP1a) following four hour pre-treatment with vehicle, 5 µM WIN or 10 µM 
THC.  Data are mean values ± SEM (n=4).  * indicates statistically significant difference 
from vehicle treatment within cell type via one-way ANOVA (p < 0.05) with post-hoc 
Neuman Keuls Multiple Comparison Test. 
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3.10 Effect of CRIP1a on CB1 receptor mediated modulation of cAMP generation in 
hCB1-HEK ( CRIP1a) cell lines. 
 CRIP1a acutely decreased spontaneous G-protein activation and the G-protein 
activation induced by certain cannabinoid ligands.  Therefore, it is of interest to 
determine if the acute modulation of CB1 receptor mediated G-protein activity translates 
into effects on CB1 receptor mediated downstream signaling events.  I hypothesize that 
CRIP1a will attenuate the constitutive inhibition of cAMP, but not agonist-mediated 
effects on cAMP, by the CB1 receptor, in agreement with results found by Neihaus et al. 
on the voltage-gated Ca
+2
 channels. 
Modulation of 10µM forskolin-stimulated cAMP generation in hCB1-HEK ( 
CRIP1a) cell lines was examined in intact cells incubated with maximally effective 
concentrations of 2 M WIN, 3 M THC, 0.2 M SR1 or vehicle (Figure 19).  In hCB1-
HEK cells, CB1 activation by the full agonist WIN caused a significant decrease in cAMP 
levels (32.7  2.96 pM cAMP in vehicle vs. 12.7  2.88 pM cAMP for WIN treatment).  
THC also appeared to cause a decrease in cAMP, but it was not significantly different 
from vehicle (20.1  1.06 pM).  The inverse agonist SR1 nearly doubled cAMP levels 
compared to control (62.0  1.9 pM).  The presence of CRIP1a did not significantly alter 
cAMP levels in the presence of vehicle alone (21.9  3.34 pM), nor the significant 
decrease in cAMP levels due to the full agonist WIN (12.7  2.77 pM, p < 0.05 different 
from vehicle condition) or cAMP levels observed with THC treatment (23.4  1.7 pM).  
Notably, CRIP1a co-expression abolished the inverse agonism of SR1, such that the levels 
of cAMP in the presence of SR1 were not significantly different from vehicle-treatment 
80 
 
in hCB1-HEK-CRIP1a cells (27.5  5.7 pM cAMP following SR1 treatment versus 21.9  
3.34 pM in vehicle treated cells).  Moreover, the levels of cAMP in the presence of SR1 
in hCB1-HEK-CRIP1a cells were significantly lower than in hCB1-HEK cells without 
CRIP1a co-expression.  Results were analyzed via one-way ANOVA, with significance 
reached at p < 0.05 (n = 8, F = 17.51, R
2
 = 0.8845). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
 
Figure 19.  Forskolin-stimulated cAMP generation in hCB1-HEK cells (CRIP1a co-
expression).  Cells were incubated with either 2 µM WIN, 3 µM THC, 0.2 µM SR1 or 
vehicle in the presence of 10 µM forskolin and phosphodiesterase inhibitors for 8 min.  
cAMP concentrations were determined using a [
3
H]cAMP kit [Liquid phase Cyclic AMP 
(PIKAPH-2).  Data are mean cAMP levels (pmol/tube)  SEM (n=4).  * indicates 
statistically significant difference from vehicle within each cell type, # indicates 
statistically significant difference comparing two cell types with the same treatment 
(ANOVA with post-hoc Newman-Keuls Test, p < 0.05).  
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3.11 Immunoblot Analysis of CB1 Receptor-mediated ERK Phosphorylation in 
hCB1-HEK ( CRIP1a) Cell Lines. 
 The modulation of intracellular kinases downstream of CB1 receptor-mediated 
generation of free G is another effector cascade that plays a role in CB1 receptor 
signaling.  I hypothesize that CRIP1a will attenuate the constitutive CB1 receptor-
mediated phosphorylation of ERK 1/2, similarly to cAMP inhibition (Figure 19). 
The effect of CRIP1a on the ability of the CB1 receptor to modulate p42/p44 MAP kinase 
(ERK 1/2) phosphorylation was examined using immunoblot techniques.  hCB1-HEK ( 
CRIP1a) cells were serum starved for 6 hours, followed by an 8 min drug treatment with 
either 2 M WIN, 3 M THC, 0.2 M SR1 or vehicle.  Cells were lysed with cell lysis 
buffer containing protease and phosphatase inhibitors and samples were immunoblotted 
and probed for ERK and p-ERK (Figure 20).   WIN, and to a lesser extent, THC, 
stimulated phosphorylation of ERK1 and ERK2 (Figure 21).  In hCB1-HEK cells, WIN 
increased ERK 1 phosphorylation to 148.64  15.61% vehicle control, and THC 
increased ERK 1 phosphorylation by 117.61  10.61% vehicle control.  No differences 
were seen in results between hCB1-HEK for hCB1-HEK-CRIP1a cells, as WIN and THC 
stimulated ERK1 phosphorylation by 140.15  1.85% vehicle control and 133.71  
10.25% vehicle control in hCB1-HEK-CRIP1a cells, respectively. 
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Figure 20.  Western blot of p44/p42 ERK phosphorylation in hCB1-HEK cells (CRIP1a 
transfection).  Membrane preparations of hCB1-HEK cells (CRIP1a transfection) (50 g) 
were probed using phosphorylated ERK 1/2 antibody (1:200 Santa Cruz) and ERK 1 
antibody for loading control (1:250, Chemicon).  Images are from one representative 
experiment of 3 replicates, and were generated using Licor Odyssey software. 
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 SR1 inhibited ERK1 phosphorylation in hCB1-HEK cells, decreasing 
phosphorylation to 69.48  25.92% vehicle control.  In hCB1-HEK-CRIP1a cells, SR1 
inhibited ERK1 phosphorylation did not appear to decrease from vehicle (90.05  
14.01% vehicle control), however, there was no statistically significant differences 
between p-ERK levels obtained in hCB1-HEK with and without CRIP1a co-expression. 
 CB1 receptor mediated phosphorylation of ERK2 followed a similar pattern to 
ERK1.  WIN and to a lesser extent, THC, stimulated ERK 2 phosphorylation (147.44  
10.66% vehicle control and 124.34  7.78% vehicle control for WIN and THC, 
respectively) in hCB1-HEK cells, with no significant differences in results seen between 
hCB1-HEK and hCB1-HEK-CRIP1a cells (145.18  10.36% vehicle control and 140.38  
5.11% vehicle control for WIN and THC, respectively, in HEK-CRIP1a cells).  Once 
again, SR1 appeared to decrease ERK2 phosphorylation to a greater exent in hCB1-HEK 
compared to hCB1-HEK-CRIP1a cells, (84.37  14.77% vehicle control in hCB1-HEK vs. 
95.56 10.89% vehicle control), however, there were no significant differences in hCB1-
HEK cells with and without CRIP1a co-expression. 
 Lysates were also immunoblotted for non-phosphorylated ERK1 and ERK2 
levels, to serve as loading controls.  No significant differences were for observed for 
ERK1 or ERK2 levels in the presence or absence of any CB1 receptor ligand.   
All data were analyzed via ANOVA, significance achieved at p < 0.05, followed 
by a post-hoc Newman-Keuls Multiple Comparison Test (n = 8, F = 4.468, R
2
 = 0.6615). 
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Figure 21.  Densitometric analysis of p44/p42 ERK 1/2 immunoblot.  The upper two 
panels show the effect of 2 µM WIN, 3 µM THC, or 0.2 µM SR1 on phosphorylation 
levels of p-44 ERK 1 (p-ERK 1, left) and p-42 ERK 2 (p-ERK 2, right).  The lower two 
panels display the loading control values of p44 ERK 1 (ERK1) and p42 ERK 2 (ERK2).  
All data are mean values  SEM expressed as normalized to vehicle alone (100%) (n=3).  
All values were derived from integrated intensity values obtained using Licor Odyssey 
software.  No statistically significant differences between the two cell types were 
observed (ANOVA with post-hoc Newman-Keuls Test, p < 0.05). 
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3.12 CRIP1a Immunoblot Analysis of Hippocampi from THC Treated Mice. 
 Results in the HEK cell model indicate that CRIP1a co-expression could alter the 
adaptation of CB1 receptors to prolonged agonist treatment in that CRIP1a inhibited WIN-
mediated CB1 receptor downregulation.  It was of interest to determine whether 
prolonged administration of cannabinoid agonists could modulate CRIP1a expression.  I 
hypothesize that CRIP1a levels will be altered in response to THC exposure, similarly to 
other CB1 receptor interacting proteins involved in receptor regulation, such as the GRKs 
and β-arrestins (Rubino et al. 2006).  CRIP1a expression in the HEK cells was driven by a 
viral promoter, and thus changes in CRIP1a expression may not be physiological relevant 
to mammalian models.  To determine if cannabinoid exposure alters CRIP1a expression in 
vivo, an animal model was used.  Hippocampus was chosen for examination, as CRIP1a 
expression in this region is very dense according to immunohistochemical staining of 
rodent brain by Dr. Maurice Elphick (unpublished data). 
 To determine whether chronic THC administration in the mice alters CRIP1a 
expression in the hippocampus, mice were treated with chronic, ramping doses (10, 20, 
30 mg/kg, 2 injections per day for 6.5 days) of THC or vehicle.  Hippocampi were 
harvested and subjected to immunoblot analysis for CRIP1a expression (Figure 22).  
Prolonged THC administration did not alter CRIP1a expression in mouse hippocampi.   
Integrated intensity of CRIP1a bands generated by the Licor Odyssey system were 24.73 
 1.31 for THC treated mice and 26.64  0.80 for vehicle treated mice, which were not 
significantly different according to a two-tailed t-test (p > 0.05, t = 1.240, df = 6).  In 
addition, mouse hippocampi were immunoblotted for the presences of -tubulin as a 
loading control.  There were no significant differences in -tubulin levels (integrated 
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intensity of 48.50  2.29 for THC treated mice and 55.01  2.43 for vehicle treated mice), 
according to a two-tailed t-test (p >  0.05, t = 1.944, df = 6). 
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Figure 22.  CRIP1a immunoblot analysis of hippocampi from THC treated male ICR 
mice.  Mice were treated with chronic, ramping doses of THC or vehicle.  A)  
Hippocampi were harvested and membrane preparations (100 g protein) were probed 
using anti-CRIP1a antisera 077.4 (Elphick, rabbit, 1:500) followed by Licor Odyssey goat 
anti-rabbit 800 CW IR dye (1:5,000).  Loading control was probed using anti--tubulin 
(Santa Cruz Biotechnology, 1:500) followed by Licor Odyssey goat anti-mouse 680 IR 
dye (1:5,000).  Images were analyzed via Licor Odyssey Infrared Imaging System.  B) 
Data are mean densitometric values  SEM (n = 4 animals for each treatment group, and 
the immunoblot was replicated twice with similar results).  There were no significant 
differences in levels of CRIP1a or -tubulin loading control between mice treated with 
THC or vehicle (students t test, p < 0.05).  
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3.13 CB1 Receptor Expression in mCB1-CHO and mCB1-CHO-CRIP1a Cell Lines. 
 Due to the modulatory effects of CRIP1a co-expression on CB1 receptor signaling 
and adaptation in the HEK cell model, it was of interest to determine whether CRIP1a co-
expression would have similar effects on CB1 receptor function in a different cell line.  
To address this question, CHO cells stably transfected with the CB1 receptor were stably 
co-transfected with CRIP1a.  Cells expressing high levels of CRIP1a were chosen for 
further study.  I hypothesize that CRIP1a will not affect CB1 receptor expression, as seen 
in the HEK cell model. 
CB1 receptor expression in mCB1-CHO and mCB1-CHO-CRIP1a cell lines were 
quantified using [
3
H]SR141716A saturation analysis. Stable transfection of CRIP1a did 
not affect CB1 receptor number (Table 7) (Bmax value of 7.71  1.63 pmol/mg in mCB1-
CHO cells versus Bmax value of 5.48  0.72 pmol/mg in mCB1-CHO-CRIP1a cells).  
Furthermore, no significant differences were seen in [
3
H]SR141716A KD values (2.08  
0.16 nM in mCB1-CHO cells versus 1.23  0.39 nM in mCB1-CHO-CRIP1a cells).  Data 
were analyzed using two-tailed t-test with significance reached at p < 0.05 (n = 4, df = 3, 
t = 1.537). 
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Table 7.  Bmax and KD values from saturation analysis of [
3
H]SR141716A binding in 
mCB1-CHO cells with and without CRIP1a co-expression.  Bmax values represent total cell 
membrane receptor levels.  Data are mean values ± SEM (n=4).  No significant 
differences between the two CHO cell types were observed (two-tailed t-test, p > 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
Bmax 
(pmol/mg) 
KD 
(nM) 
mCB1-CHO 7.72 ± 1.63 2.08 ± 0.16 
mCB1-CHO-CRIP1a  5.48 ± 1.23 1.23 ± 0.39 
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3.14 Stoichiometric Relationship of CRIP1a to CB1 Receptor in mCB1-CHO and 
mCB1-CHO-CRIP1a Cell Lines. 
 To determine the stoichiometric relationship of CRIP1a to CB1 receptor in mCB1-
CHO and mCB1-CHO-CRIP1a cell lines, immunoblot analysis of CRIP1a was performed 
using a GST-pulldown purified CRIP1a concentration curve for comparison to cell line 
samples and analyzed on the Licor Odyssey system (Figure 23).  I hypothesize, that like 
HEK cells, CRIP1a transfection will increase the stoichiometric relationship of CRIP1a to 
CB1 receptor.  CRIP1a concentrations were inferred from a linear regression of the 
concentration curve in Micrsoft Excel, and the unknown CRIP1a concentrations of mCB1-
CHO and mCB1-CHO-CRIP1a membrane preparations were determined (Table 8).  
mCB1-CHO-CRIP1a cells express significantly more CRIP1a than mCB1-CHO cells (7720 
 1370 pmol/mg in mCB1-CHO-CRIP1a cells versus 63.1  18.0 pmol/mg in mCB1-CHO 
cells) according to two-tailed t-test (p = 0.0021, df = 8, t = 4.461).  
 CB1 receptor levels and CRIP1a concentrations were used to generate 
stoichiometric ratios for mCB1-CHO and mCB1-CHO-CRIP1a cell lines (Table 8).  The 
molar ratio of CRIP1a/CB1 receptor was significantly higher in mCB1-CHO-CRIP1a cells 
(1930  343 pmol/mg) than in mCB1-CHO-CRIP1a cells (15.7  4.52) as analyzed by 
two-tailed t-test (p = 0.0021, df = 8, t = 4.461). 
 Comparison of the molar ratio of CRIP1a/CB1 receptors in rat cerebellum (33.6 ± 
5.19) and mCB1-CHO cells (± CRIP1a transfection), revealed that the molar ratio of 
CRIP1a/CB1 receptors found in mCB1-CHO cells without CRIP1a transfection (15.7  
4.52) was closer to that found in rat cerebellum than the ratio found in the mCB1-CHO-
CRIP1a cell line (1930  343 pmol/mg).  Additionally the molar ratio of CRIP1a/CB1 
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receptors in mCB1-CHO cells was greater than the molar ratio of CRIP1a/CB1 receptors 
found in either hCB1-HEK or hCB1-HEK-CRIP1a cell lines (ANOVA with Newman-
Keuls Multiple Comparisons post-hoc test, p < 0.05). 
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Figure 23.  Quantitative western blot analysis of CRIP1a concentration in mCB1-CHO 
cells (CRIP1a transfection).  CRIP1a purified via GST-pulldown methodology generated 
a CRIP1a concentration curve.  Membrane preparations of mCB1-CHO cells (CRIP1a 
transfection) (70 g/sample) were probed using anti-CRIP1a antisera 077.4 (Elphick, 
rabbit, 1:500) followed by Licor Odyssey goat anti-rabbit 800 CW IR dye (1:5,000).  
Images were analyzed via Licor Odyssey Infrared Imaging System.  Unknown CRIP1a 
concentrations were calculated using linear regression on Microsoft Excel.  Image is 
representative of immunoblot of 3 replicates. 
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CB1 
(pmol/mg) 
CRIP1a  
(pmol/mg) 
Molar Ratio 
(CRIP1a/CB1) 
mCB1-CHO 7.72 ± 1.63 63.1 ± 18.0 15.7 ± 4.52 
mCB1-CHO-
CRIP1a  
5.48 ± 1.23 7720 ± 1370* 1930 ± 343* 
 
Table 8.  Stoichiometric molar ratio of CRIP1a/CB1 receptor in mCB1-CHO cells 
(CRIP1a transfection).  Data are mean values  SEM (n=4).  Bmax values represent total 
cell membrane CB1 receptor levels.  Stable CRIP1a transfection caused a significant 
increase in CRIP1a expression, creating a significant molar excess relative to CB1 receptor 
expression (* = p < 0.05 different from mCB1-CHO cells lacking CRIP1a transfection in 
two-tailed t-test).  
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3.15 CRIP1a Modulation of Ligand-Specific CB1 Receptor-Mediated G-protein 
Activation; [
35
S]GTPS Binding Studies in mCB1-CHO ( CRIP1a) Cell Lines. 
 To determine the effects of CRIP1a over-expression on CB1 receptor mediated G-
protein activation by specific cannabinoid ligands, [
35
S]GTPS binding assays were 
performed in mCB1-CHO ( CRIP1a) cell lines with WIN, THC and SR1 (Figure 24).  I 
hypothesize that greater CRIP1a expression will decrease the constitutive and high 
efficacy ligand activation of CB1 receptor-mediated G-protein activity, similarly to the 
HEK cell model. 
Unlike results in hCB1-HEK-CRIP1a cell line, the CRIP1a significantly increased 
WIN stimulated Emax values (228.0  26.58% in mCB1-CHO-CRIP1a cells versus 122.61 
 36.50% in mCB1-CHO cells) according to two-tailed t-test (p < 0.05, n = 5, df = 4, t = 
3.731) (Figure 29).   Over-expression of CRIP1a also significantly increased the percent 
stimulation by a single, maximally effective concentration (6 M) of THC (125.7  
11.4% in mCB1-CHO-CRIP1a cells vs. 83.6  19.9% in mCB1-CHO cells) according to 
two-tailed t-test analysis (p < 0.05, n = 4, df = 3, t = 4.033). 
Notably, CRIP1a significantly decreased the inverse agonism of SR1 (Emax value 
of 27.33  7.18% in mCB1-CHO-CRIP1a cells versus 39.10  4.31% in mCB1-CHO cells, 
as indicated by two-tailed t-test (p < 0.05, n = 4, df = 3, t = 5.644).  This finding is in 
agreement with results seen in hCB1-HEK cells with and without CRIP1a co-expression. 
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Figure 24.  [
35
S]GTPS binding in mCB1-CHO and mCB1-CHO-CRIP1a cells.  
Concentration effect curves were generated for WIN and SR1. Data points are mean % 
stimulation  SEM (n=4).  All experiments performed in the presence of 100 mM NaCl. 
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Figure 25.  Emax values for WIN and SR1 and percent stimulation for THC in membranes 
from mCB1-CHO cells with and without over-expression of CRIP1a.  Data are mean 
values  SEM (n=4).  A) CRIP1a expression significantly increased the Emax value of 
WIN and decreased the negative Emax value of the inverse agonist SR1.  B)  CRIP1a 
significantly increased the % stimulation by 6 µM THC. 
*
 p < 0.05 different from the 
corresponding drug in non-CRIP1a expressing cells by two-tailed t-test.  # p < 0.01 
different from the corresponding drug in non-CRIP1a expressing cells by two tailed t-test.  
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3.16 The Effects of CRIP1a on Spontaneous CB1 G-protein Activation; [
35
S]GTPS 
in mCB1-CHO ( CRIP1a) Cell Lines with Varying Na
+
 Levels. 
 To examine the effects of CRIP1a on spontaneous CB1 G-protein activation, 
mCB1-CHO cells were incubated with maximally effective concentrations of WIN (10 
M), THC (6 M), SR1 (0.05 M) or under basal conditions as well as incubated with 
increasing concentrations of NaCl (0-175 mM) (Figure 26).  Decreasing NaCl 
concentrations lead to greater overall G-protein activity for all treatment conditions.  
However, CRIP1a had no effect on G-protein activation at the various NaCl 
concentrations in the presence or absence of WIN, THC or SR1 as analyzed by two-way 
ANOVA, significance reached at p < 0.05. 
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Figure 26.  [
35
S]GTPS binding in mCB1-CHO cells (CRIP1a over-expression) with 
varying NaCl concentrations.  Cells were incubated with maximally effective 
concentrations agonist concentrations (10 M WIN, 6 µM THC) and a maximally 
inhibiting concentration of the inverse agonist SR1 (0.5 M SR1) in the presence of 
varying concentrations of NaCl (0-150 mM).  Data points are mean [
35
S]GTPS bound 
(fmol/mg)  SEM (n=6).  No statistical differences were found between the two cell 
types (ANOVA with post-hoc Newman-Keuls Test (p < 0.05). 
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3.17 Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry 
(LC-ESI-MS-MS) Analysis of Endocannabinoids in mCB1-CHO ( CRIP1a) Cell 
Lines. 
 LC-ESI-MS-MS was utilized to measure the endocannabinoid levels of of AEA 
or 2-AG.  I hypothesize that CRIP1a will not affect endocannabinoid levels, as in the HEK 
cell model.  For mCB1-CHO cells with and without CRIP1a over-expression, 3 samples of 
whole cells (10 x 10
6
 cells) or membrane preparations (1,000 g) were analyzed (Table 
9).  No detectable levels of AEA were found in whole cell or membrane preparations of 
mCB1-CHO ( CRIP1a) cell lines.  No detectable levels of 2-AG were found in the 
membrane preparations of mCB1-CHO ( CRIP1a) cell lines.  However, 2-AG was 
detected in whole cell extracts of mCB1-CHO cells (0.074  0.0020 nmol), which was 
significantly increased by the over-expression of CRIP1a (0.22  0.020 nmol) (two-tailed 
t-test, p = 0.0023, df = 4, t = 6.949). 
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 AEA (pmol) 2-AG (nmol) 
mCB1-CHO 
Whole cells (10 x 10
6
) 
None Detected 0.074 ± 0.0020 
mCB1-CHO 
Membrane prep (1,000 g) 
None Detected None Detected 
mCB1-CHO -CRIP1a 
Whole cells (10 x 10
6
) 
None Detected 0.22 ± 0.020* 
mCB1-CHO -CRIP1a 
Membrane prep (1,000 g) 
None Detected None Detected 
 
Table 9.  Endocannabinoid levels in mCB1-CHO cells (CRIP1a over-expression).   
Liquid chromatography electrospray ionization tandem mass spectrometry determined the 
levels of two endocannabinoids, AEA and 2-AG, in whole cell and membrane 
preparations of mCB1-CHO cells (CRIP1a over-expression). Data are mean values 
(nmols)  SEM (n=3).  No AEA was detected in either cell line or either preparation type.  
CRIP1a over-expression significantly up-regulated 2-AG levels in whole cell preparations 
of mCB1-CHO cells (students t-test, p = 0.0023), however no 2-AG was detected in 
membrane preparations of either cell type. 
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Chapter 4.  Conclusions. 
 
4.1 CB1 Receptor Expression; Effect of CRIP1a Transfection and Cell Confluency 
 CB1 receptor expression was not affected by CRIP1a co-transfection when 
comparing hCB1-HEK and hCB1-HEK-CRIP1a cell lines at 100% confluency (Table 2), 
in agreement with Neihaus et al., and the proposed hypothesis that CRIP1a does not affect 
total expression levels of the CB1 receptor.  This lack of effect of CRIP1a on CB1 receptor 
expression at high confluency is particularly convenient for studies comparing effects on 
CB1 receptor function in HEK cells, as alterations in CB1 receptor signaling can be 
directly attributed to CRIP1a and not to alterations in CB1 receptor levels. 
 Furthermore, KD values were unaffected by the presence of CRIP1a, indicating 
that CRIP1a did not alter the binding of [
3
H]SR141716A to the CB1 receptor.  Therefore, 
CRIP1a effects on inverse agonist properties of SR1 are unlikely to be due to changes in 
affinity of the CB1 receptor for SR1. 
 Low cell confluency decreased CB1 receptor expression in hCB1-HEK cells, but 
not hCB1-HEK-CRIP1a cells (Figure 9).  Cell confluency affects protein expression in 
cultured cells (Wolthuis et al. 1993).  Low CB1 receptor expression in low confluency 
hCB1-HEK cells may be due to the greater growth rate of low confluency cells.  During 
rapid cell proliferation, expression of transfected proteins may be suppressed, as 
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proposed in the hypothesis that CB1 receptor expression would be negatively influenced 
by cell confluency.  However, this effect was not seen in cells co-transfected with 
CRIP1a, suggesting that CRIP1a co-expression may stabilize the expression of the CB1 
receptor in rapidly dividing cells.  CB1 receptor levels were not affected by cell 
confluences above 95% in either cell line.  Therefore, cells were harvested for use at 95% 
confluency or above for all further experiments. 
4.2 Stoichiometric Relationship of CRIP1a/CB1 Receptor in hCB1-HEK ( CRIP1a) 
Cell Lines and Mouse Cerebellum. 
 The stoichiometric molar ratio of CRIP1a/CB1 receptor in hCB1-HEK cells was 
less than one (0.376), compared to hCB1-HEK-CRIP1a cells in which the ratio was greater 
than one (5.47), and was increased by CRIP1a transfection as hypothesized (Table 3).  
This allowed for the comparison of a cell line in which the CB1 receptor is in excess over 
CRIP1a in hCB1-HEK cells compared to a cell line in which CRIP1a is in excess to the 
CB1 receptor in hCB1-HEK-CRIP1a cells.  The physiological relevance of the CRIP1a/CB1 
receptor ratio in hCB-HEK-CRIP1a cells was verified in mouse cerebellum, where the 
native stoichiometric molar ratio of CRIP1a/CB1 receptor was significantly greater than 
one (33.6), indicating that under physiological conditions, CRIP1a exerts its biological 
effect when there are more than sufficient CRIP1a molecules per CB1 receptor.  
Cerebellum was chosen for this comparison because dense, uniform CB1 receptor 
expression in the molecular layer of the cerebellar cortex (Herkenham et al. 1991; Tsou et 
al. 1998), closely resembles a similar dense uniform immunoreactivity of CRIP1a in the 
cerebellar cortex (Elphick et. al, unpublished data), compared to other brain regions.  
Furthermore, the molecular layer of the cerebellum contains one of the densest CB1 
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receptor expressions in the brain, suggesting a uniform distribution of these receptors, 
making the cerebellum an appropriate location for stoichiometric comparison 
(Herkenham et al. 1991).  However, whole cerebellum was used for experiments, due to 
the difficulty of anatomical dissection of the molecular layer.  Even if only one-third of 
the CRIP1a expressed in the cerebellum was co-localized in the same cells as the CB1 
receptor, the CRIP1a/CB1 ratio would be no less than in the stably co-transfected HEK 
cell model used the present studies.  Therefore, it seems likely that hCB1-HEK-CRIP1a 
cells express CRIP1a in a molar excess relative to the CB1 receptor that is no greater than 
that found in native rat cerebellum. When compared to hCB1-HEK cells which lack 
sufficient CRIP1a to interact with each CB1 receptor molecule, the hCB1-HEK-CRIP1a 
cell line can serve as a reasonable model system to assess the effects of CRIP1a on CB1 
receptor function. 
4.3 CRIP1a Modulation of Acute CB1 Receptor Mediated G-protein Activation in 
HEK Cells. 
 CRIP1a decreased acute CB1 receptor-mediated G-protein activation by the high 
efficacy agonists Nol Eth, HU210, WIN and CP, while leaving acute receptor-mediated 
G-protein activation by MethA, Levo, and THC unaffected in [
35
S]GTPS binding studies 
(Figure 11 and Figure 12).  All experiments were performed in the presence of 100 mM 
NaCl.  Under these conditions, CRIP1a affects certain cannabinoid ligands, but not others.  
The first obvious difference between Nol Eth, HU210, WIN, CP and the unaffected 
cannabinoid ligands is efficacy.  Nol Eth, HU210, WIN and CP all behave as high 
efficacy agonists in these studies, with Emax values of 100% or greater in hCB1-HEK cells 
without CRIP1a transfection (Figure 16).  In the presence of CRIP1a the Emax value of Nol 
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Eth to approximately 100%, whereas those of HU210, WIN and CP were reduced to ≤ 
80%.  Incidentally, this value is approximately equivalent to the Emax values of the next 
most efficacious ligands, MethA and Levo.  One possibility is that CRIP1a reduces G-
protein activation by the CB1 receptor only when receptor activity is near maximal, thus 
preferentially affecting high efficacy cannabinoid ligands. 
Another, less likely, possibility is that CRIP1a affects cannabinoid ligands with 
certain structural characteristics.  WIN is a structurally distinct aminoalkylindol that 
binds differentially to the CB1 receptor.  A mutation at position 5.46 from Val to Phe in 
the CB1 receptor alters the affinity of WIN for the CB1 receptor, while leaving the CB1 
receptor affinity of HU210, CP, and AEA unaffected (Song et al. 1999).  However, CP is 
a nonclassical synthetic cannabinoid that is different from classical synthetic 
cannabinoids but still resembles THC to a degree, making this hypothesis slightly less 
probable than the efficacy hypothesis stated above.  Furhermore, HU210 is a high 
efficacy analog of the low efficacy partial agonist THC (Breivogel et al. 2001) and Nol 
Eth is a high efficacy eicosanoid that is structurally related to the moderate efficacy 
cannabinoid MethA (Sugiura et al. 1999).  These structure-activity relationships argue 
against structural features as the main determining factor in the effects of CRIP1a.  Thus, 
the effects of CRIP1a on acute CB1 receptor-mediated G-protein activation are more 
likely to be dependent on the efficacy of the ligand. 
CRIP1a may also affect ligands that stimulate certain Gi protein subtypes.  WIN 
activates all three Gi subtypes (see Introduction 1.3), whereas MethA only stimulates 
Gi3 and acts as an inverse agonist for Gi1 and Gi2 (Mukhopadhyay and Howlett 
2005).  It is not known what Gi subtypes are specifically activated by the other 
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cannabinoid ligands used in the [
35
S]GTPS binding experiments.  CRIP1a may only 
affect ligands that interact with Gi1, Gi2, or Go such as WIN, while leaving ligands 
that primarily activate Gi3, such as MethA, unaffected. 
CRIP1a attenuated the apparent ability of SR1 to act as an inverse agonist in the 
[
35
S]GTPS binding studies.  This finding suggests that CRIP1a inhibits the constitutive 
activity of the CB1 receptor, in agreement with studies by Neihaus et al. (2007), which 
found that CRIP1a inhibited constitutive inhibition of voltage gated Ca
+2
 channels (See 
Introduction 1.6).  Another possibility is that CRIP1a affects SR1 due to the Gi subtypes 
it affects.  SR1 acts as an inverse agonists for all three Gi subtypes (Mukhopadhyay and 
Howlett 2005).  One of these three subtypes may be preferentially affected by CRIP1a. 
The juxtamembrane CB1 receptor C-terminus recognizes Gαi3 and Gαo, making them 
more likely candidates for interference by CRIP1a than Gαi1 and Gαi2, which interact 
with the C3 loop (Mukhopadhyay and Howlett 2001; Mukhopadhyay et al. 2002).  
Furthermore, Gαi3 is associated with constitutive activity of the CB1 receptor, further 
suggesting it may be a candidate for CRIP1a interference (Anavi-Goffer et al. 2007).  
However, this hypotheses is mutually exclusive to the hypothesis that MethA is 
unaffected by CRIP1a because it only activates Gi3.  Future experiments examining the 
effects of CRIP1a on CB1 receptor-Gα intereactions will need to be done to test these 
hypotheses. 
4.4 CRIP1a Attenuates Constitutive CB1 Receptor Activity & Spontaneous CB1 
Receptor Mediated G-protein Activation in HEK Cells. 
 CRIP1a decreased the ability of SR1 to act as an inverse agonist in [
35
S]GTPS 
binding studies, which suggests that CRIP1a decreases the constitutive activity of the 
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receptor.  Importantly, this is in agreement with the earlier Neihaus et. al. study, which 
demonstrated a decrease in the inverse agonism of SR1 in electrophysiology studies using 
a voltage-step Ca
+2
 current protocol.  To further examine the effects of CRIP1a on 
spontaneous CB1 receptor G-protein activation, [
35
S]GTPS binding experiments were 
conducted over a range of Na
+
 concentrations (0-150 mM NaCl) (Figure 13).  In addition, 
several levels of ligand-induced CB1 receptor activation were examined [basal activity, 
occupancy by the high effcicay agonist WIN (10 M), occupancy by the partial agonist 
THC (6 M) and occupancy by the full inverse agonist SR1 (0.5 M SR1)].  Na+ acts as 
a negative allosteric modulator of GPCR activity (Koski et al. 1982).  As NaCl 
concentrations decreased, CB1 receptor-mediated G-protein activation spontaneously 
increased for both cell types for all conditions tested, as indicated by increased net 
inhibition by SR1.  CRIP1a decreased WIN simulated CB1 receptor activation at all NaCl 
concentrations, in agreement with previous results obtained in the present studies using 
100 mM NaCl (Fig 15 & 16) 
The effects of CRIP1a became more evident as spontaneous CB1 receptor activity 
increased, in agreement with the proposed hypothesis that CRIP1a inhibits spontaneous 
CB1 receptor-mediated activity.  CRIP1a significantly decreased G-protein activation for 
all conditions tested at low NaCl concentrations (0, 10 & 25 mM NaCl).  This finding 
suggests that CRIP1a is able to affect the CB1 receptor, not only for when it is stimulated 
by certain ligands, but under any conditions when the CB1 receptor is highly active.  This 
includes THC and basal conditions, which were not affected by CRIP at 100 mM NaCl 
(Figure 11 & Figure 12). 
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When basal [
35
S]GTPS binding was subtracted from the data at all NaCl 
concentrations, the significant effects of CRIP1a at lower NaCl concentrations were lost 
for all conditions (Figure 14).  This finding suggests that CRIP1a decreased an equal 
amount of spontaneous G-protein activity under all conditions tested, including basal.  
This spontaneous G-protein activity seen at low Na
+
 concentrations was in addition to the 
CB1 receptor-mediated G-protein activation that was modulated by the cannabinoid 
ligands, as represented by the difference between the levels of [
35
S]GTPS binding in the 
presence of a full agonist and an inverse agonist.  However, the decrease in net WIN-
stimulated CB1 receptor-mediated G-protein activation in the presence of CRIP1a was 
statistically significant at higher NaCl concentrations (75, 100, 125 & 150 mM NaCl).  
This finding suggests that CRIP1a can decrease G-protein activity in more than one 
fashion.  Not only does CRIP1a decrease spontaneous G-protein activation as seen at low 
NaCl concentrations, but CRIP1a also net decreases WIN-stimulated CB1 receptor-
mediated G-protein activation at moderate to high NaCl concentrations as seen in Figure 
14. 
Furthermore, these net stimulated [
35S]GTPγS binding data were subject to AUC 
analysis (Figure 15).  CRIP1a significantly decreased the AUC for WIN-stimulated CB1 
receptor-mediated G-protein activation in hCB-HEK cells compared to hCB-HEK-
CRIP1a cells.  The AUC was not significantly different for THC or SR1 treatment 
between the two cell types.  However, there was a trend for CRIP1a to decrease the 
apparent inverse agonism by SR1.  The lack of SR1 effect may be due to the small 
apparent constitutive CB1 receptor-mediated G-protein activity seen in hCB-HEK cells 
(SR1 Emax value of –13.34  1.65% in hCB-HEK cells in the presence of 100 mM NaCl, 
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Figure 16).  Also, since Na
+
 and inverse agonists both stabilize the R state of the receptor, 
the efficacy of inverse agonists is reduced in the presence of Na
+
 (Seifert and Wenzel 
Seifert, 2002), which may also account for the lack of statistically significant effects of 
CRIP1a on SR1.   
To further examine the effect of CRIP1a on spontaneous CB1 receptor activity, the 
same conditions were tested (basal, WIN, THC and SR1), at normal (100 mM) and low 
(0 mM) NaCl concentrations, with the additional test condition of PTX pretreatment (Fig 
16).  PTX treatment ADP-ribosylates inhibitory Gi/o protein  subunits (Locht and 
Antoine 1995), inhibiting their interaction with GPCRs, thus allowing a distinction 
between GPCR-dependent G-protein activation and spontaneously active G-proteins.  
Under normal, 100 mM NaCl, conditions, CRIP1a significantly decreased WIN-
stimulated G-protein activity, in as seen in previous experiments.  There were no 
statistical differences for basal G-protein activity and SR1 inhibited G-protein activity 
under 100 mM NaCl conditions between hCB1-HEK cells with and without CRIP1a co-
expression.  The lack of difference under basal conditions is in agreement with earlier 
experiments.  However, earlier experiments showed a decrease in inverse agonism by 
SR1 in the presence of CRIP1a.  This may be due to the very small amount of constitutive 
activity seen in hCB1-HEK cells, which is generally 13% at 100 mM NaCl.  Previous 
experiments utilized an SR1 concentration-effect curve (Figure 11 & 12), which added 
statistical power to the SR1 analysis that the current experiment lacked.  PTX 
pretreatment significantly decreased G-protein activation for all conditions in hCB1-HEK 
cells.  Interestingly, PTX pretreatment only significantly decreased WIN-stimulated G-
protein activity in hCB1-HEK-CRIP1a cells, while PTX pretreatment did not make a 
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significant difference for basal or SR1-inhibited conditions.  This finding suggests that 
the presence of CRIP1a in hCB1-HEK-CRIP1a cells reduces G-protein activity to levels 
indistinguishable from PTX pretreatment, further supporting the theory that CRIP1a 
reduces spontaneous GPCR-dependent G-protein activation. 
Once again, the absence of NaCl magnified the effect of CRIP1a.  Under 0 mM 
NaCl concentration, CRIP1a significantly decreased G-protein activation for the basal, 
WIN and SR1 conditions, in agreement with the previous experiment (Figure 13).  The 
increase of spontaneous GPCR activity due to the absence of NaCl created a significant 
difference for all conditions with and without PTX in hCB1-HEK-CRIP1a cells, indicating 
that CRIP1a is not as effective as PTX in ameliorating spontaneous G-protein activation 
under these conditions.  Importantly, the presence of CRIP1a had no effect in cells that 
were pretreated with PTX, such that G-protein activity in hCB1-HEK was not different 
from that in hCB1-HEK-CRIP1a cells after PTX pretreatment PTX regardless of the 
presence or absence of agonist or inverse agonist, indicating that all inhibitory effects of 
CRIP1a are on GPCR-dependent G-protein activity, in agreement with the proposed 
hypothesis. 
In these experiments, the ability of CRIP 1a to reverse the apparent inverse 
agonism of SR1 was not detected as in earlier experiments (Figure 12).  As stated earlier, 
this may be due to the relatively low amount of constitutive CB1 receptor activity in hCB-
HEK cells.  Furthermore, the concentration of SR1 used, which was maximally effective, 
may have been high enough to affect GPCRs other than the CB1 receptor under certain 
conditions.  At concentrations over 1 M, SR1 is able to affect both basal and WIN or 
AEA-induced stimulation of [
35
S]GTPS binding in CB1 receptor knockout mouse brain 
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membranes (Breivogel et al. 2001).  This finding raises the possibility that SR1 affects 
GPCRs other than the CB1 receptor near this concentration.  Additionally, in a study 
characterizing SR1-inhibited G-protein activity by measuring [
35
S]GTPS binding in rat 
cerebellar membranes found that SR1 acts as a competitive antagonist at nM 
concentrations, whereas it inhibits basal receptor-mediated G-protein activity at 
micromolar concentrations (Sim-Selley et al. 2001).  This finding also suggests that SR1 
may affect GPCRs other than the CB1 receptor, and/or that SR1 binds to different sites on 
the CB1 receptor to produce inverse agonist versus competitive agonist effects.  It is 
conceivable that at the concentration used in these studies, SR1 may be partially affecting 
receptor activity other than that of the CB1 receptor, confounding interpretation of the 
effect of CRIP1a on CB1 receptor-mediated G-protein activation.  Some evidence for this 
possibility is seen in the present study.  [
35
S]GTPS binding studies utilizing a 
concentration effect curve for SR1 show a reduced ability for CRIP1a to inhibit the 
apparent inverse agonist effects of SR1 at the highest concentrations examined (Figure 
11).  This effect may be due to interference by other non-CB1 receptor-mediated effects 
of SR1.  Therefore, the ability of CRIP1a to inhibit the constitutive activity of the CB1 
receptor may not be as apparent at high SR1 concentrations. 
Another potentially confounding variable in experiments examining effects of 
CRIP1a on constitutive CB1 receptor activity is the possibility of the presence of 
endogenous cannabinoids.  The effects of CRIP1a on apparently spontaneous CB1 
receptor-mediated G-protein activity could be misinterpreted if in fact endogenous 
cannabinoids are contributing to this basal activity.  To ensure that differences in basal G-
protein activation seen between hCB1-HEK and hCB1-HEK-CRIP1a cells were due to the 
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presence of CRIP1a and not differences in endogenous cannabinoid expression, 
endocannabinoid levels were measured in whole cells and membrane preparations from 
each cell line (Table 4).  No detectable levels of AEA or 2-AG were found in either 
preparation of either cell line. 
Collectively, the data indicate that CRIP1a decreases not only constitutive activity, 
and high efficacy agonist-stimulated stimulated CB1 receptor-mediated G-protein 
activity, but possibly non CB1 receptor-mediated G-protein activity under any conditions 
when spontaneous GPCR activation is high. 
4.5 CRIP1a Decreases CB1 Receptor Downregulation, but not CB1 Receptor 
Desensitization. 
   To assess the effect of CRIP1a on CB1 receptor regulation by prolonged agonist 
treatment, hCB1-HEK cells (± CRIP1a co-expression) were pretreated for four hours with 
agonist (10 µM WIN, 6 µM THC or vehicle), followed by MethA-stimulated [
35
S]GTPS 
binding (Figure 17).  MethA was chosen as the stimulating ligand in these studies 
because CRIP1a did not affect its ability to acutely stimulate CB1 receptor-mediated G-
protein activation in earlier studies (Figure 11 and Figure 12).  Both the high efficacy 
agonist WIN, and to a lesser extent, the partial agonist THC, caused significant 
desensitization of the CB1 receptor, as indicated by decreased Emax values for MethA 
stimulated G-protein activation in agonist pretreated cells.  However, the presence of 
CRIP1a did not significantly affect this desensitization, in opposition to the proposed 
hypothesis that CRIP1a could sterically interfere with GPCR C-terminal interacting 
proteins that mediate homologous desensitization, such as GRKs or -arrestins.  
Nonetheless, the inability of CRIP1a to affect CB1 receptor desensitization is not 
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surprising.  CRIP1a binds to the last nine amino acids of the CB1 receptor C-terminal tail, 
which is some distance from the CB1 C-terminal region required for GRK or -arrestin 
binding and CB1 receptor desensitizaiton (aa 419-438) (Jin et al. 1999), therefore making 
steric hinderance of GRK or -arrestin binding less likely. 
 Interestingly, the MethA EC50 values for WIN and THC pre-treated cells were 
significantly increased in both hCB1-HEK ( CRIP1a) cell lines (Table 5), as a result of 
rightward shifts of the MethA concentration-effect curves (Figure 17).  For many GPCRs, 
only a fraction of available receptors need to be occupied for an agonist to produce a full 
functional response.  Further receptor occupancy beyond the maximal response produces 
no further stimulation, and this situation is referred to as receptor reserve.  Receptor 
reserve can be measured in a biological system by inactivating an increasing percentage 
of receptors, such as with an irreversible antagonist, which will produce a progressive 
rightward shift in the dose-response curve that is subsequently followed by a depression 
in the maximal response.  CB1 receptors in particular are known for their large receptor 
reserve for downstream cannabinoid actions in the central nervous system (Gifford et al. 
1999).  However, the receptor reserve for CB1 receptor mediated G-protein activation 
may not be as large, as demonstrated in heterozygous CB1 knockout mice (Selley et al. 
2001), but there could be receptor reserve for G-protein activation in transfected cell 
lines, as shown with the μ opioid system comparing CHO cells transfected with μ opioid 
receptor to rat brain (Selley et al. 1998).  In this study, the decrease in MethA EC50 values 
is indicative of loss of receptor reserve due to downregulation of the CB1 receptor, as 
seen in the next set of experiments measuring loss of receptors in response to WIN and 
THC pretreatment. 
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 The effects of CRIP1a on CB1 receptor downregulation was determined using the 
same four hour drug pretreatment followed by [
3
H]SR141716A saturation analysis to 
determine changes in CB1 receptor number (Figure 18).  In hCB1-HEK cells, the partial 
agonist THC caused a robust CB1 receptor downregulation, while the full agonist WIN 
caused less downregulation.  CRIP1a attenuated the less substantial CB1 downregulation 
induced by WIN, but did not significantly attenuate the robust downregulation induced 
by THC, although there appeared to be a trend toward a decrease.  [
3
H]SR141716A KD 
values were unaffected by drug treatment (Table 6), indicating the effective removal of 
WIN and THC that were used for the pretreatment prior to assay.  This finding suggests 
that rightward shifts in the MethA concentration-effect curves induced by drug 
pretreatment were due to a loss in receptor reserve and not residual pretreatment drug in 
the membranes.  One possible explanation for the differential ability of CRIP1a to inhibit 
WIN- versus THC-induced CB1 receptor downregulation may be that CRIP1a weakly 
sterically hinders the interaction of -arrestin with the phosphorylated receptor.  -
arrestins are sizable (~48 kDa) proteins that interact near the C-terminal tail of the CB1 
receptor and interact with GPCRs strongly enough to relocate them from signaling 
complexes to clathrin-coated pits (Reiter and Lefkowitz 2006).  It is possible that in this 
cell model CRIP1a is able to sterically interference with WIN-stimulated interactions of 
-arrestin and the CB1 receptor in a way that THC is able to overcome.   
 Another possibility is differential induction of the -arrestin types by THC and 
WIN.  HEK 293 cells contain both -arrestin 1 and 2.  In HEK 293 cells transfected with 
the µ opiod receptor (µOR), the µOR interacts with -arrestin 2 only when the partial 
agonist morphine is used.  However, when the full agonist etorphine is utilized, the µOR 
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receptor interacts with both -arrestin 2 and 1 (Bohn et al. 2004).  Furthermore, the 
genetic knockout of -arrestin 2 in mice selectively enhanced the behavioral effects of 
THC, while leaving the effects of CP, MethA, JWH-073 and O-1812 unaffected 
(Breivogel et al. 2008).  Therefore, THC may be preferentially affect -arrestin 2 binding 
to the CB1 receptor.  It is possible that with the CB1 receptor, THC and WIN cause 
differential recruitment of -arrestin 2 and 1, and that CRIP1a preferentially interferes 
with the binding of one of these isoforms, namely -arrestin 1. 
 Alternatively, CRIP1a may attenuate WIN-induced CB1 receptor downregulation 
by interfering with GASP1 binding to the CB1 receptor.  GASP1 is required for ligand-
induced downregulation of the CB1 receptor (Martini et al. 2007), but is not directly 
involved in CB1 receptor desensitization, thus potentially explaining the ability of  
CRIP1a to interfere with downregulation but not desensitization, as hypothesized.  The 
robust downregulation induced by THC compared to WIN may indicate that THC 
induces greater CB1 receptor/GASP1 interactions than WIN.  CRIP1a may not sterically 
hinder this stronger interaction induced by THC as effectively as the putatively weaker 
interaction of CB1 receptor to GASP1 induced by WIN.  This difference may account for 
CRIP1a preferentially affecting WIN over THC-mediated downregulation. 
 Downregulation by WIN could also be more greatly affected by CRIP1a because 
CRIP1a inhibits acute G-protein activation by WIN, which could result in impairment of 
Gβγ recruitment of GRK 2/3.   Another related possibility is that CRIP1a affects WIN-
stimulated CB1 receptor regulation due to the specific G subtypes that WIN activates, as 
hypothesized for acute CB1 receptor-mediated G-protein activation (see Conclusions 4.3).  
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However, these explanations seem less likely as CRIP1a affected downregulation of the 
CB1 receptor without affecting CB1 receptor desensitization. 
 The time course used in the CB1 receptor desensitization and downregulation 
experiments may have played a part in the observed results.  CRIP1a had no effect on 
desensitization of the CB1 receptor after four hours of drug exposure (Figure 17).  
Maximal endocytosis of the CB1 receptor is observed in desacetyllevonantradol (DALN) 
exposed CB1-HEK cells after 1 hour (Keren and Sarne 2003).  CRIP1a may affect 
desensitization on a shorter time scale, before maximal desensitization is reached.  Thus, 
if CRIP1a inhibits the rate of desensitization but not the maximal level of desensitization, 
then it is possible that maximal desensitization was achieved well before 4 hours, and the 
effect of CRIP1a was not evident at this time point.  Future experiments should examine 
the effects of CRIP1a on desensitization in time increments less than 1 hour.  
Additionally, effects of CRIP1a on THC-induced downregulation may have been apparent 
on a shorter time scale.  CB1 receptors are downregulated by more than 75% in WIN-
exposed CB1-HEK cells after 3 hours (Martini et al. 2007).  Subsequent experiments 
examining the effects of CRIP1a on downregulation may yield significant results at one 
and two hour time points, regardless of the agonist occupying the receptor. 
 Lastly, the cannabinoid ligand concentrations used may have played a role in the 
observed effects of CRIP1a on CB1 receptor desensitization and downregulation.  
Maximally effective concentrations of WIN (10 µM) and THC (6 µM) were used in both 
experiments.  Desensitization is increased by increasing WIN concentrations as measured 
by cannabinoid inhibition of Ca
+2
 spiking activity in hippocampal neurons (Kouznetsova 
et al. 2002).  Also, increasing concentrations of DALN increased CB1 receptor 
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endocytosis in CB1-HEK cells (Keren and Sarne 2003).  Therefore, lower cannabinoid 
concentrations may be used to reveal subtle effects of CRIP1a on the potency of agonists 
to induce CB1 receptor desensitization and downregulation.  Future experiments 
examining the effects of CRIP1a on CB1 receptor regulation should include concentration-
effect curves that begin at sub-EC50 ligand concentrations. 
4.6 CRIP1a and Downstream Signaling of CB1 Receptors 
 The effects of CRIP1a on downstream CB1 receptor mediated inhibition of 
forskolin stimulated cAMP generation were measured via liquid phase cAMP radioassay 
(Figure 19).  CRIP1a did not alter cAMP levels in cells treated with WIN, THC or vehicle.  
However, interestingly, CRIP1a reversed the apparent inverse agonism of SR1.  The 
ability of CRIP1a to decrease inverse agonism, a measure of the constitutive activity of 
the CB1 receptor, in cAMP experiments agrees with the results obtained when measuring 
the effects of CRIP1a on constitutive CB1 receptor activity in [
35
S]GTPS binding 
experiments.  Moreover, these results are in agreement with the ability of CRIP1a to 
decrease CB1 receptor-mediated tonic inhibition of voltage-gated Ca
+2
 channels by 
Neihaus et al. (2007).  Therefore, CRIP1a appears to decrease the spontaneous modulation 
of certain downstream effectors by CB1 receptors, as hypothesized. 
 The effects of CRIP1a on downstream CB1 receptor-stimulated ERK 1/2 
phosphorylation were examined via immunoblot analysis using an antibody that is 
specific for phosphorylated ERK 1/2 (Figure 20).  WIN, and to a lesser extent THC, 
increased ERK 1 and 2 phorsphorylation, and SR1 inhibited ERK 1 and 2 
phosphorylation (Figure 21).  There was no statistical differences in agonist-stimulated 
ERK 1 or 2 phosphorylation between hCB1-HEK cells with and without CRIP1a co-
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expression, suggesting that CRIP1a had no significant effect on downstream ERK 1/2 
signaling by CB1 receptors. 
 However, it should be noted that there was a trend for CRIP1a to reverse the 
ability of SR1 to produce inverse agonism in the phosphorylation of ERK 1 and 2.  
However, this effect was also not statistically significant.  It is possible that this 
immunblot assay protocol was not sensitive enough to detect differences between hCB1-
HEK cells with and without CRIP1a co-expression.  Future protocols more sensitive to 
changes in CB1 receptor-dependent phorsphorylation of ERK 1 and 2 may yet detect an 
effect by CRIP1a.  Furthermore, future experiments could utilize a concentration-effect 
curve, as CRIP1a may lead to potency changes in the ability of cannabinoids to 
phosphorylate ERK 1/2.  A similar argument could be made for agonist-inhibited cAMP 
generation above.   
Furthermore, the concentration of SR1 used, which was maximally effective, may 
have been too high to see significant effects of CRIP1a on the CB1 receptor-mediated 
phosphorylation of ERI 1/2.  At this dose it might have GPCR effects not specific to the 
CB1 receptor that may be affecting the results, as discussed for PTX pre-treatment 
experiments in Conclusions 4.4.   
 Considering the effect of CRIP1a on downstream signaling to both cAMP and 
ERK 1/2, it seems probable that CRIP1a affects some downstream signals but not others.  
In addition, CRIP1a could differentially modulate G versus G-mediated signaling.  
However, CRIP1a decreased the constitutive CB1-mediated inhibition of cAMP, which is 
modulated mainly by G1 (Howlett et al. 2002), and decreased the constitutive inhibition 
of voltage-gated Ca
+2
 channels (Niehaus et al. 2007), which is modulated by G 
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(Herlitze et al. 1996).  Thus CRIP1a is apparently able to modulate G-protein mediated 
downstream signals despite whether Gα or Gβγ is required for downstream signaling.  
Therefore, it remains uncertain why SR1-stimulated cAMP generation was significantly 
inhibited by CRIP1a co-expression, whereas SR1-inhibited ERK 1/2 phosphorylation was 
not.  Aside from methodological issues, it is possible that there is greater amplification of 
the cAMP signal provided by the catalytic action of the adenylyl cyclase enzyme, relative 
to less amplification in the signaling cascade leading to ERK 1/2 phosphorylation.  If so, 
then this differential amplification might explain the greater signal for SR1-modulated 
activity in the cAMP than in the ERK 1/2 experiments. 
4.7 Mouse hippocampal CRIP1a expression in response to THC administration. 
 Expressions of various regulators of CB1 receptor signaling are altered in 
response to chronic cannabinoid treatment.  Chronic, but not acute, THC treatment 
upregulates GRK2, GRK4, -arrestin 1, and -arrestin 2 (Rubino et al. 2006).  To 
determine if chronic drug administration could alter CRIP1a levels in the hippocampus, 
mice were administered ramping doses of THC and their hippocampi were dissected and 
immunoblotted for CRIP1a expression (Figure 22).  CRIP1a levels were not different 
between mice administered THC or vehicle.  Chronic THC administration did not alter 
CRIP1a expression in the hippocampus of mice in response to repeated ramping doses of 
THC administration.  This was not in agreement with the predicted hypothesis that THC 
treatment would affect CRIP1a levels.  GRKs and β-arrestins are proteins involved in CB1 
receptor adaptation to prolonged agonist treatment, and therefore it is not surprising that 
prolonged agonist treatment affects their expression.  CRIP1a regulates the acute and 
constitutive responsiveness of the CB1 receptor; therefore regulation of CRIP1a 
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expression in response to prolonged agonist occupancy might be unnecessary.  However, 
it would be interesting to examine the effects of WIN on CRIP1a expression, as the 
downregulation induced by the CB1 receptor occupancy by WIN was affected by the co-
expression of CRIP1a.  
4.8 Stoichiometric Relationship of CRIP1a/CB1 Receptor in mCB1-CHO Cells with 
and without CRIP1a Co-expression. 
 CB1 receptor (Table 7) and CRIP1a levels (Figure 22) were quantified in mCB1-
CHO cells with and without stable co-transfection of CRIP1a, and the CRIP1a/CB1 
receptor molar stoichiometric relationship was calculated from these values (Table 8).  
mCB1-CHO cells without CRIP1a transfection contained a substantial amount of CRIP1a.  
The stoichiometric molar ratio in mCB1-CHO cells without CRIP1a transfection was 
greater than hCB1-HEK cells with stable CRIP1a transfection (Table 3).  Stable CRIP1a 
transfection further increased CRIP1a expression dramatically in mCB1-CHO cells, as 
hypothesized, creating a nearly 2,000-fold molar excess of CRIP1a/CB1 receptor, which 
can be viewed as CRIP1a over-expression. 
4.9 CRIP1a Modulation of Acute CB1 Receptor Mediated G-protein Activation in 
CHO Cells. 
 The effects of CRIP1a on acute CB1 receptor-mediated G-protein activation were 
examined in [
35
S]GTPS binding studies using WIN, THC and SR1 in mCB1-CHO cell 
membranes with and without CRIP1a over-expression (Figure 24 and Figure 25).  
Notably, further over-expression of CRIP1a in mCB1-CHO-CRIP1a cells further decreased 
constitutive activity of CB1 receptors compared to mCB1-CHO cells which already 
contained ample levels of CRIP1a, as hypothesized.  This finding raises the further 
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possibility that CRIP1a did not reliably reduce constitutive CB1 receptor activity in all 
experiments in hCB1-HEK-CRIP1a cells (especially under low sodium concentrations) 
because it was not expressed at a sufficiently high molar ratio compared to CB1 receptor 
levels. 
 Surprisingly, CRIP1a over-expression in mCB1-CHO cells increased maximal CB1 
receptor-mediated G-protein activation by both WIN and THC, in opposition to the 
proposed hypothesis.   Therefore, stoichiometric relationship could be a critical 
determinant in how CB1 receptor-mediated G-protein activation responds acutely to the 
presence of CRIP1a.  Over-expression of CRIP1a in co-transfected CB1-CHO cells caused 
augmentation of acute agonist-stimulated CB1 receptor-mediated G-protein activation, 
rather than the attenuation seen at near physiological CRIP1a levels present in CRIP1a co-
transfected CB1-HEK cells. 
 Alternatively, the effects of CRIP1a may be cell type dependent.  CHO and HEK 
cell lines are two of the most commonly used cell lines in biomedical research.  CHO 
cells, derived from Chinese Hamster Ovary cells (Puck et al. 1958) are the most utilized 
cell line in the pharmaceutical large scale production of therapeutic protein products, 
accounting for billions of dollars in products annually (Andersen and Krummen 2002).  
However, the genome of CHO cells is not well characterized (Wlaschin et al. 2005).  In 
contrast, HEK cells, derived from Human Embryonic Kidney cells (Graham et al. 1977) 
are postulated to be derived from a neuronal cell lineage (Shaw et al. 2002).  Notably, a 
HEK genomic database at the University of Florida 
(http://www.mbi.ufl.edu/~shaw/293.html) reveals that HEK cells contain a surprising 
amount of neuron-specific proteins including several neurofilament subunits and alpha 
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internexin, as well as GPCRs, such as dopamine (D2) receptors and neurotensin (NTR2) 
receptors.  Additionally, CHO and HEK cells are different in the subtypes of Gi that 
they express.  CHO cells express Gi2 and Gi3, but not Gi1 (Gettys et al. 1994).  On 
the other hand, HEK cells express Gi1 and Gi3 but not Gi2 (Law et al. 1993).  
Therefore, CRIP1a‟s differential effects on acute agonist stimulated G-protein activity 
may be due to the differences in the proteome of HEK and CHO cell types, rather than to 
differences in the stoichiometric relationships between CRIP1a and CB1 receptor in the 
two cell lines.  
Future experiments examining the effects of genetic silencing of CRIP1a 
expression using shRNA in CHO cells may be able to answer the question of cell type 
specificity.  In this case CRIP1a silencing could be expected to reverse both the 
attenuation of constitutive activity and augmentation of agonist stimulated CB1 receptor-
mediated G-protein activation in mCB1-CHO cells.  It is also possible that partial 
silencing of CRIP1a expression in mCB1-CHO cells, to a molar ratio similar to that 
obtained in hCB1-HEK-CRIP1a cells, could produce attenuation of full agonist-stimulated 
G-protein activation.  
 Another explanation may be that the CRIP1a differentially affects the human and 
mouse CB1 receptor.  However, this explanation is less likely due to expression of CRIP1a 
throughout the vertebrates and the identical amino acid composition of the last 9 amino 
acids of both murine and human CB1 receptors, which compromise the CRIP1a binding 
site. 
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4.10 CRIP1a Does Not Affect Spontaneous CB1 Receptor Mediated G-protein 
Activation in CHO Cells. 
 Varying NaCl concentrations were used to determine the effect of CRIP1a on 
spontaneous G-protein activation in mCB1-CHO cells with and without CRIP1a over-
expression in the presence of WIN, THC, SR1 and basal conditions (Figure 26).  No 
effect of CRIP1a on spontaneous or agonist-stimulated G-protein activation was found, 
thus rejecting the proposed hypothesis.  This was in contrast to results seen in earlier 
ligand concentration-effect curves in the presence of 100 mM NaCl, in which CRIP1a 
over-expression suppressed the inverse agonist effects of SR1 and augmented CB1 
receptor-mediated G-protein activation by agonists.  
 The most likely explanation for these different results involves the manner in 
which the membrane preparations for these experiments were prepared.  Unlike all other 
experiments in this dissertation, mCB1-CHO cells (±CRIP1a) were grown in flasks, drug-
treated, homogenized and frozen back into aliquots which were later used in [
35
S]GTPS 
binding studies.  Freeze-thawing membrane preparations may impair the acute signaling 
of the CB1 receptor or its modulation by CRIP1a and explain the variability and lack of 
effect of CRIP1a seen in these results.  Also notable, fresh membrane preparations were 
used in initial [
3
H]SR141716A saturation analysis of hCB1-HEK and mCB1-CHO cell 
lines with and without CRIP1a transfections (Table 3 and Table 8) .  However, excess 
remaining protein from [
35
S]GTPS binding studies was often frozen back and used in 
[
3
H]SR141716A saturation analysis to confirm unchanging CB1 receptor numbers.  No 
differences between fresh and frozen membrane preparations were seen in the results of 
[
3
H]SR141716A saturation analysis.  This finding is unsurprising as freezing back 
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membrane preparations is more likely to upset the more delicate signaling process 
assayed in receptor-stimulated [
35
S]GTPS binding studies rather than the number of CB1 
receptors determined by high affinity [
3
H]SR141716A saturation analysis. 
 Another potential explanation is the comparison of stoichiometric relationship 
between the HEK and CHO cell line models.  mCB1-CHO cells, unlike hCB1-HEK cells 
contain a substantial amount of CRIP1a, resulting in a molar excess of CRIP1a over CB1 
receptor that is merely enhanced by CRIP1a over-expression in this cell line.  Therefore, 
comparing an excess of CRIP1a to an even greater excess of CRIP1a relative to the CB1 
receptor might result in no discernable effects of CRIP1a over a range of Na
+
 
concentration.  However, this explanation is less likely, as an effect of CRIP1a on 
constitutive and agonist-induced CB1 receptor-mediated G-protein activity was seen at 
100 mM NaCl. 
4.11 CRIP1a Transfection Affects 2-AG Expression in mCB1-CHO (±CRIP1a) Cell 
Lines. 
 Levels of two endocannabiniods, AEA and 2-AG were determined via LC-ESI-
MS-MS for mCB1-CHO cells with and without CRIP1a over-expression (Table 9).  No 
detectable levels of AEA were found in either cell line in either whole cell or membrane 
preparations.  Contrariwise, whole cell preparations of mCB1-CHO cells contained small 
amounts of 2-AG which were significantly increased in CRIP1a over-expressing mCB1-
CHO-CRIP1a cells, which was not predicted by the hypothesis.  2-AG can act as an 
autocrine mediator, as it is responsible for the postsynaptic slow self-inhibition of 
neocortical low-threshold spiking interneurons (Marinelli et al. 2008).  CRIP1a co-
expression may feedback onto 2-AG synthesis, thus increasing 2-AG levels in mCB1-
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CHO- CRIP1a cells.  However, this difference cannot explain the results seen in earlier 
[
35
S]GTPS binding studies comparing the two CHO cell lines, as no detectable levels of 
2-AG were found in the membrane preparations of either cell line.  Nonetheless, 
downstream signaling experiments utilizing mCB1-CHO cells with and without CRIP1a 
over-expression may not accurately reflect the effects of CRIP1a on basal CB1 receptor 
activity due to the increase in 2-AG in CRIP1a over-expressing whole cells.  Downstream 
experiments utilized whole cells which were drug treated and harvested for analysis of 
cAMP and pERK 1/2 levels, which could be affected by the endogenous presence of 2-
AG.  Conversely, endogenous cannabinoids could not have affected downstream cAMP 
and phosphorylated ERK 1/2 signals in hCB1-HEK cells with and without CRIP1a 
transfection, as no endogenous cannabinoids were detected in these cell lines. 
4.12 Summary of CRIP1a Conclusions 
 In summary, CRIP1a inhibits the constitutive activity of the CB1 receptor (Figure 
27, Table 10).  Additionally, CRIP1a modulates acute CB1 receptor mediated G-protein 
activation of high efficacy ligands in a manner that is cell type dependent and/or 
dependent on the stoichiometric relationship of CRIP1a to the CB1 receptor.  CRIP1a does 
not affect the maximal level of CB1 receptor desensitization, but does modify CB1 
receptor downregulation induced by WIN.  Lastly, CRIP1a affects downstream 
constitutive CB1 receptor-mediated signaling for cAMP inhibition, but not the 
phosphorylation of ERK 1/2.  CRIP1a also appears to modulate 2-AG production only in 
certain cell types (i.e. CHO) when expressed as sufficiently high levels. 
 Overall, CRIP1a mediates numerous CB1 receptor effects while being a small 17 
kD protein.  This observation, in tandem with the fact that CRIP1a contains a PDZ Class I 
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ligand, suggests that CRIP1a mediates it effects in concert with other proteins to which it 
binds.  For example, CRIP1a may bind to members of the cell cytoskeleton, thus 
stabilizing the CB1 receptor and preventing its constitutive activation and activation by 
high efficacy ligands.  A possible parallel example to this may be the recently discovered 
Homer proteins, which bind to metabotropic glutamate (mGlu) receptors and cytoskeletal 
Shank proteins.  Homer proteins decrease the constitutive activity of the mGlu receptors, 
much like CRIP1a decreases the constitutive activity of the CB1 receptor (Ango et al. 
2001; Bockaert et al. 2004).  Future studies should seek to discover other CRIP1a protein 
binding partners. 
 Physiologically, the ability of CRIP1a to affect high efficacy ligands while leaving 
moderate and low efficacy ligands unaffected may be important in the differential 
regulation of endocannabinoid signals generated by the CB1 receptor.  For instance, AEA 
is a partial agonist (Breivogel et al. 1998), as is its stable analog, MethA, used in the 
present study.  CRIP1a did not affect MethA stimulation of the CB1 receptor, and 
presumably will not affect stimulation by its partial efficacy analog AEA.  However, 2-
AG is a full agonist (Stella et al. 1997), and noladin ether, another high efficacy agonist 
that is structurally similar to 2-AG, was affected by CRIP1a in this study.  Therefore, it is 
reasonable to speculate that CRIP1a will modify the CB1 receptor-mediated G-protein 
signal generated by 2-AG but not by AEA.  Therefore, under physiological conditions, 
CRIP1a may affect the signaling of certain endogenous cannabinoids but not others. 
 Overall, CRIP1a may be key to modulating CB1 receptor functions; allowing the 
generation of certain therapeutic responses while minimizing deleterious side effects.  For 
example, pharmacological modulation of CRIP1a, rather than direct modulation of the 
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CB1 receptor, may allow the therapeutic modulation of high efficacy endocannbinoid 
effects while avoiding any side effects generated by the modulation of partial efficacy 
endocannabinoids.   
In conclusion, CRIP1a is an important member of the CB1 receptor receptosome 
that regulates both constitutive activity of the CB1 receptor and ligand-mediated CB1 
receptor activity in a manner that differentially affects high efficacy and partial agonists, 
both of exogenous and endogenous origin.  Additional evidence suggests that CRIP1a can 
also attenuate agonist-induced CB1 receptor downregulation and constitutive CB1 
receptor modulation of a subset of effector pathways.  These properties suggest that 
CRIP1a may someday be targeted pharmacologically to allow more effective 
manipulation of CB1 receptor activities to therapeutic advantage. 
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Figure 27.  The effects of Cannabinoid Receptor Interacting protein (CRIP1a) on CB1 
receptor function.  CRIP1a inhibited constitutive G-protein activation by the CB1 receptor.  
CRIP1a decreased WIN and CP-stimulated acute G-protein activation by the CB1 receptor 
in HEK cells and increased WIN and THC-stimulated acute G-protein activation by the 
CB1 receptor in CHO cells.  CRIP1a did not affect desensitization, but did attenuate 
downregulation induced by WIN occupancy of the CB1 receptor.  Downstream, CRIP1a 
decreased the constitutive inhibition of adenylyl cylase by the CB1 receptor. The effects 
of CRIP1a were dependent on the stoichiometric ratio of CRIP1a/CB1 receptors. 
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Table 10.  Concluding summary of the effects of CRIP1a on CB1 receptor mediated 
activity.  References: (1) Neihaus et al. (2007), (2) Results from the current dissertation. 
 
 
 
 
 
 
 
 
 
 
 
CRIP1a Effects? Constitutive  Agonist-Mediated  
CB1 Receptor 
Expression 
No (1, 2) None apparent. 
G-protein Activation Yes (2) Yes (2) 
Receptor 
Desensitization 
None apparent. No (2) 
Receptor 
Downregulation 
None apparent. Yes (2) 
Ca+2 Channel 
Inhibition 
Yes (1) No (1) 
Adenylyl Cyclase 
Inhibition 
Yes (2) No (2) 
ERK 1/2 No (2) No (2) 
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